<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340027</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-100</org_study_id>
    <secondary_id>2010-020601-32</secondary_id>
    <nct_id>NCT01340027</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder</brief_title>
  <acronym>Symphony</acronym>
  <official_title>A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine how well two medicines in combination (solifenacin
      succinate and mirabegron) work in the treatment of bladder problems over a 12-week period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to End of Treatment (EOT) in Mean Volume Voided Per Micturition</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The average volume voided per micturition was calculated from the volume of each micturition measured by the participant and recorded in a micturition diary for 3 days before the Baseline and Week 12 clinic visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The average number of micturitions (urinations) per 24 hours was derived from the number of urinations (excluding incontinence only episodes) per day recorded by the participant in the micturition diary for 3-days before the Baseline and Week 12 clinic visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The average number of incontinence episodes (any involuntary leakage of urine) per day was derived from the number of incontinence episodes recorded by the participant in the micturition diary for 3-days before the Baseline and Week 12 clinic visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Visit in Mean Volume Voided Per Micturition</measure>
    <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
    <description>The average volume voided per micturition was calculated from the volume of each micturition measured by the participant and recorded in a micturition diary for 3 days before the Baseline and each post-baseline clinic visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Visit in Mean Number of Micturitions Per 24 Hours</measure>
    <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
    <description>The average number of micturitions (urinations) per 24 hours was derived from the number of urinations (excluding incontinence only episodes) per day recorded by the participant in the micturition diary for 3-days before the Baseline and each post-baseline clinic visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Micturition Response</measure>
    <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
    <description>A responder is defined as a participant with at most 8 micturitions per 24 hours post-baseline and a negative change (i.e. an improvement) from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Visit in Mean Number of Incontinence Episodes Per 24 Hours</measure>
    <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
    <description>The average number of incontinence episodes (any involuntary leakage of urine) per day was derived from the number of incontinence episodes recorded by the participant in the micturition diary for 3-days before the Baseline and each post-baseline clinic visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Zero Incontinence Episodes Post-baseline</measure>
    <time_frame>Weeks 2, 4, 8 and 12</time_frame>
    <description>The percentage of participants with no incontinence episodes for the 3 days prior to each clinic visit derived from the micturition diary recorded by the participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With 50% Reduction in Incontinence Episodes</measure>
    <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
    <description>The percentage of participants with at least a 50% decrease from Baseline in mean number of incontinence episodes per 24 hours during the 3 days prior to each clinic visit derived from the participant's micturition diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Visit in Mean Number of Urgency Incontinence Episodes Per 24 Hours</measure>
    <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
    <description>Urgency incontinence is the involuntary leakage of urine accompanied by or immediately preceded by urgency, and was derived from the number of incontinence episodes classified by the participant in a 3-day micturition diary as Grade 3 or 4 on the Patient Perception of Intensity of Urgency Scale: 0 = No urgency; 1 = Mild urgency; 2 = Moderate urgency, could postpone voiding a short while; 3 = Severe urgency, could not postpone voiding; 4 = Urge incontinence, leaked before arriving to the toilet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Visit in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours</measure>
    <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
    <description>The average number of urgency episodes (the sudden, compelling desire to pass urine, which is difficult to defer), derived from urgency episodes classified by the participant in the 3-day micturition diary as grade 3 or 4 on the Patient Perception of Intensity of Urgency Scale: 0: No urgency; 1: Mild urgency; 2: Moderate urgency, could delay voiding a short while; 3: Severe urgency, could not delay voiding; 4: Urge incontinence, leaked before arriving to the toilet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Visit in Mean Level of Urgency</measure>
    <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
    <description>Average of participants' ratings on the degree of urgency associated with each micturition and/or incontinence episode recorded in the 3-day micturition diary according to the Patient Perception of Intensity of Urgency Scale: 0: No urgency; 1: Mild urgency; 2: Moderate urgency, could delay voiding a short while; 3: Severe urgency, could not delay voiding; 4: Urge incontinence, leaked before arriving to the toilet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Visit in Mean Number of Pads Used Per 24 Hours</measure>
    <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
    <description>The average number of times a participant recorded a new pad used per day during the 3-day micturition diary period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Visit in Mean Number of Nocturia Episodes Per 24-Hours</measure>
    <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
    <description>Nocturia is defined as waking at night one or more times to void. The average number of times a participant urinated (excluding incontinence only episodes) during sleeping time per day was derived from the 3-day micturition diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Treatment in Patient Perception of Bladder Condition (PPBC)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The PPBC scale is a global assessment tool that asks patients to rate their impression of their current bladder condition on a 6-point scale from 1: 'Does not cause me any problems at all'; 2: 'Causes me some very minor problems'; 3: 'Causes me some minor problems'; 4: 'Causes me (some) moderate problems'; 5: 'Causes me severe problems' and 6: 'Causes me many severe problems'. A negative change from Baseline score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement in PPBC</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The PPBC scale is a global assessment tool that asks patients to rate their impression of their current bladder condition on a 6-point scale from 1: 'Does not cause me any problems at all'; 2: 'Causes me some very minor problems'; 3: 'Causes me some minor problems'; 4: 'Causes me (some) moderate problems'; 5: 'Causes me severe problems' and 6: 'Causes me many severe problems'. Improvement was defined as at least a 1-point improvement (decrease) from Baseline in PPBC score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Major Improvement in PPBC</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The PPBC scale is a global assessment tool that asks patients to rate their impression of their current bladder condition on a 6-point scale from 1: 'Does not cause me any problems at all'; 2: 'Causes me some very minor problems'; 3: 'Causes me some minor problems'; 4: 'Causes me (some) moderate problems'; 5: 'Causes me severe problems' and 6: 'Causes me many severe problems'. Major improvement was defined as at least a 2-point improvement (decrease) from Baseline in PPBC score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Deterioration in PPBC</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The PPBC scale is a global assessment tool that asks patients to rate their impression of their current bladder condition on a 6-point scale from 1: 'Does not cause me any problems at all'; 2: 'Causes me some very minor problems'; 3: 'Causes me some minor problems'; 4: 'Causes me (some) moderate problems'; 5: 'Causes me severe problems' and 6: 'Causes me many severe problems'. Deterioration was defined as at least a 1 point increase from Baseline in PPBC score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Treatment in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Overactive bladder symptoms were assessed using the symptom bother scale of the overactive bladder questionnaire. The symptom bother scale consists of 8 questions answered by the participant on a scale from 1-6. The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 to 100, with 100 indicating worst severity. A negative change from Baseline in symptom bother score indicates improvements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Symptom Bother Response</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Overactive bladder symptoms were assessed using the symptom bother scale of the overactive bladder questionnaire. The symptom bother scale consists of 8 questions answered by the participant on a scale from 1-6. The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 to 100, with 100 indicating worst severity. Symptom bother response is defined as improvement (decrease) of at least 10 points from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Treatment in Health-related Quality of Life (HRQL) Total Score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Health-related quality of life was assessed by the HRQL subscales (coping, concern, sleep and social interaction) of the overactive bladder questionnaire (OABq). The HRQL total score was calculated by adding the 4 HRQL subscale scores, and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from Baseline in HRQL score indicates improvements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Health-related Quality of Life Total Score Response</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Health-related quality of life was assessed by the HRQL subscales (coping, concern, sleep and social interaction) of the overactive bladder questionnaire (OABq). The HRQL total score was calculated by adding the 4 HRQL subscale scores, and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. HRQL response is defined as improvement (decrease) of at least 10 points from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Mobility Score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The EQ-5D is an international, standardized, nondisease-specific (i.e., generic) instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their health state:
I have no problems in walking about; I have some problems in walking about; I am confined to bed.
In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of patients in that category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Self-care Score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The EQ-5D is an international, standardized, nondisease-specific (i.e., generic) instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their health state:
I have no problems with self-care; I have some problems washing or dressing myself; I am unable to wash or dress myself.
In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of patients in that category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The EQ-5D is a standardized, nondisease-specific instrument for describing health status. Participants were asked which statement best describes their health state with regard to usual activities (work, study or leisure): I have no problems performing my usual activities; I have some problems performing my usual activities; I am unable to perform my usual activities.
In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of patients in that category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The EQ-5D is an international, standardized, nondisease-specific (i.e., generic) instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their health state:
I have no pain or discomfort; I have moderate pain or discomfort; I have extreme pain or discomfort. In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of participants in that category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The EQ-5D is an international, standardized, nondisease-specific (i.e., generic) instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their health state:
I am not anxious or depressed; I am moderately anxious or depressed; I am extremely anxious or depressed. In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of patients in that category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Treatment in European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The EQ-5D is an international, standardized, generic instrument for describing and evaluating health status. Health status is assessed by patients evaluating their health on a vertical, visual analog scale from 0 to 100 where the endpoints are labeled 'Worst imaginable health state' (=0) and 'Best imaginable health state' (=100). On the EQ-5D VAS, a positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Treatment in Work Productivity and Activity Impairment (WPAI)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>This 6-item assessment measures productivity losses during the past 7 days and includes measures on work time missed due to health, impairment while working due to health (the participant's assessment of the degree to which health affected their productivity while working), overall work impairment due to health (takes into account both hours missed due to health and the participant's assessment of the degree to which health affected their productivity while working) and activity impairment due to health (the degree in which health problems affected their ability to do regular daily activities). Scores for each measure are expressed from 0 to 100 with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Treatment in Treatment Satisfaction on Visual Analog Scale (TS-VAS)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The TS-VAS is a visual analog scale (VAS) that asks patients to rate their satisfaction with treatment by placing a vertical mark on a 10 cm line where the endpoints are labeled 'No, not at all' on the left (=0) to 'Yes, completely satisfied' on the right (=10). A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">1307</enrollment>
  <condition>Urinary Bladder, Overactive</condition>
  <condition>Urinary Bladder Diseases</condition>
  <condition>Urologic Diseases</condition>
  <condition>Urological Manifestations</condition>
  <condition>Signs and Symptoms</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received matching placebo tablets orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirabegron 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirabegron 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin 2.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin 5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin 2.5 mg and Mirabegron 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin 2.5 mg and Mirabegron 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin 5 mg and Mirabegron 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin 5 mg and Mirabegron 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin 10 mg and Mirabegron 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin 10 mg and Mirabegron 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>oral</description>
    <arm_group_label>Mirabegron 25 mg</arm_group_label>
    <arm_group_label>Mirabegron 50 mg</arm_group_label>
    <arm_group_label>Solifenacin 2.5 mg and Mirabegron 25 mg</arm_group_label>
    <arm_group_label>Solifenacin 2.5 mg and Mirabegron 50 mg</arm_group_label>
    <arm_group_label>Solifenacin 5 mg and Mirabegron 25 mg</arm_group_label>
    <arm_group_label>Solifenacin 5 mg and Mirabegron 50 mg</arm_group_label>
    <arm_group_label>Solifenacin 10 mg and Mirabegron 25 mg</arm_group_label>
    <arm_group_label>Solifenacin 10 mg and Mirabegron 50 mg</arm_group_label>
    <other_name>YM178</other_name>
    <other_name>Myrbetric</other_name>
    <other_name>Myrbetriq</other_name>
    <other_name>Betanis</other_name>
    <other_name>Betmiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin succinate</intervention_name>
    <description>oral</description>
    <arm_group_label>Solifenacin 2.5 mg</arm_group_label>
    <arm_group_label>Solifenacin 5 mg</arm_group_label>
    <arm_group_label>Solifenacin 10 mg</arm_group_label>
    <arm_group_label>Solifenacin 2.5 mg and Mirabegron 25 mg</arm_group_label>
    <arm_group_label>Solifenacin 2.5 mg and Mirabegron 50 mg</arm_group_label>
    <arm_group_label>Solifenacin 5 mg and Mirabegron 25 mg</arm_group_label>
    <arm_group_label>Solifenacin 5 mg and Mirabegron 50 mg</arm_group_label>
    <arm_group_label>Solifenacin 10 mg and Mirabegron 25 mg</arm_group_label>
    <arm_group_label>Solifenacin 10 mg and Mirabegron 50 mg</arm_group_label>
    <other_name>Vesicare</other_name>
    <other_name>Vesikur</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion Criteria at Visit 1/Screening:

               -  Subject has a Body Mass Index (BMI) of between 18 and 35 kg/m^2 and a total body
                  weight between 50 and 95 kg;

               -  Subject is willing and able to complete the micturition diary and questionnaires
                  correctly and is willing and able to measure his/her vital signs at home at
                  stipulated time points, using the device provided by the study personnel, and to
                  adequately record the readings;

               -  Subject has symptoms of overactive bladder (OAB; urinary frequency, urgency
                  and/or urgency incontinence) for at least 3 months.

          -  Inclusion Criteria at Visit 3/Baseline:

               -  Subject has experienced frequency of micturition on average ≥ 8 times per 24-hour
                  period during the 3-day micturition diary period (incontinence episode should not
                  be counted as a micturition);

               -  Subject must experience at least 1 episode of urgency (grade 3 or 4) per 24-hour
                  period (with or without urgency incontinence) during the 3 day micturition diary
                  period.

        Exclusion Criteria:

          -  Exclusion Criteria at Visit 1/Screening:

               -  Subject is breastfeeding, pregnant or intends to become pregnant during the
                  study. The pregnancy test (Beta Human Chorionic Gonadotropin in serum) at
                  Screening must be negative in women of childbearing potential;

               -  Female subjects of childbearing potential and not using a highly effective method
                  of birth control during the study and for 30 days after final study drug
                  administration.

               -  Male subjects (unless surgically sterile) with female spouses/partners who are of
                  childbearing potential, and not using a barrier method of contraception during
                  the study and for 30 days after final study drug administration. In addition,
                  female spouses/partners of male subjects and who are of childbearing potential
                  should also use a highly effective method of birth control during the study and
                  for 30 days after final study drug administration. Highly effective methods of
                  birth control are defined as those, alone or in combination, that result in a low
                  failure rate (i.e. less than 1% per year) when used consistently and correctly.

               -  Subject has significant post-void residual (PVR) volume (&gt; 150 mL);

               -  Subject has significant stress incontinence or mixed stress/urgency incontinence
                  where stress is the predominant factor as determined by the Investigator (for
                  female subjects confirmed by the cough provocation test);

               -  Subject has a neurological cause for detrusor overactivity;

               -  Subject has an indwelling catheter or practices intermittent
                  self-catheterization;

               -  Subject has diabetic neuropathy;

               -  Subject has chronic inflammation such as interstitial cystitis, bladder stones,
                  previous pelvic radiation therapy or previous or current malignant disease of the
                  pelvic organs;

               -  Subject has had previous lower urinary tract or pelvic floor surgery (except
                  cystoscopy);

               -  Subject has had intravesical treatment in the past 12 months with e.g., botulinum
                  toxin, resiniferatoxin, capsaicin;

               -  Subject has uncontrolled narrow angle glaucoma, urinary or gastric retention,
                  severe ulcerative colitis or Crohn's Disease, toxic megacolon, myasthenia gravis
                  or any other condition which makes the use of anticholinergics contraindicated;

               -  Subject has clinically significant cardiovascular or cerebrovascular diseases
                  within 6 months prior to Screening, such as myocardial infarction, uncontrolled
                  angina, significant ventricular arrhythmias, heart failure and stroke;

               -  Subject is receiving current non-drug treatment including electro-stimulation
                  therapy (with the exception of a bladder training program or pelvic floor
                  exercises which started more than 30 days prior to Screening);

               -  Subject is using medications intended to treat OAB or prohibited medications.

               -  Subject has known or suspected hypersensitivity to solifenacin succinate,
                  mirabegron or any of their excipients;

               -  Subject has any significant neurological disease or defect affecting bladder
                  function (e.g., neurogenic bladder, systemic or central neurological disease such
                  as multiple sclerosis [MS] and Parkinson's disease);

               -  Subject has severe hypertension which is defined as a sitting average systolic
                  blood pressure ≥ 180 mmHg and/or an average diastolic blood pressure ≥ 110 mmHg;

          -  Exclusion Criteria at Visit 2/Placebo Run-In:

               -  Subject has evidence of a urinary tract infection (UTI) (urine culture containing
                  &gt; 100,000 cfu/mL). The subject can be enrolled into the study after successful
                  treatment of the UTI (confirmed by a laboratory result of negative urine
                  culture). However, the subject must be re screened if the initial screening visit
                  was &gt; 28 days;

               -  Subject has a QT interval &gt; 450 ms or is at risk of QT prolongation (e.g., family
                  history of long QT syndrome, hypokalaemia) or is on drug treatment known to be
                  associated with QT prolongation;

               -  Subject has clinically significant abnormalities on the 12 lead electrocardiogram
                  (ECG);

               -  Subject has serum creatinine &gt; 150 µmol/L, aspartate aminotransferase (AST)
                  and/or alanine aminotransferase (ALT) &gt; 2x upper limit of normal (ULN),
                  gamma-glutamyltransferase (γ-GT) &gt; 3x ULN, or total bilirubin &gt; 2x ULN, as
                  assessed in Screening samples;

          -  Exclusion Criteria at Visit 3/Baseline:

               -  Subject had an average total daily urine volume &gt; 3000 mL as recorded in the
                  micturition diary period;

               -  Subject has severe hypertension which is defined as a sitting average systolic
                  blood pressure ≥ 180 mmHg and/or an average diastolic blood pressure ≥ 110 mmHg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Physician</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bristol Urological Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BY37101</name>
      <address>
        <city>Minsk</city>
        <zip>220036</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BY37102</name>
      <address>
        <city>Minsk</city>
        <zip>220119</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BY37103</name>
      <address>
        <city>Minsk</city>
        <zip>223010</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BY37104</name>
      <address>
        <city>Vitebsk</city>
        <zip>210037</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BE32102</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BE32104</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BE32103</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BE32101</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ42005</name>
      <address>
        <city>Bohumín</city>
        <zip>73581</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ42003</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ42011</name>
      <address>
        <city>Ostrava</city>
        <zip>700 30</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ42006</name>
      <address>
        <city>Plzen</city>
        <zip>301 24</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ42007</name>
      <address>
        <city>Prague 4</city>
        <zip>14000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ42001</name>
      <address>
        <city>Prague</city>
        <zip>128 51</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ42009</name>
      <address>
        <city>Prague</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ42010</name>
      <address>
        <city>Roudnice nad Labem</city>
        <zip>413 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ42012</name>
      <address>
        <city>Sternberk</city>
        <zip>78501</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ42002</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>68608</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DK45101</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DK45102</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DK45104</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FI35803</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FI35804</name>
      <address>
        <city>Kouvola</city>
        <zip>45200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FI35801</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FI35802</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR33104</name>
      <address>
        <city>Colmar Cedex</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR33108</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR33103</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR33111</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR33112</name>
      <address>
        <city>Paris cedex 20</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR33106</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR33110</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE49109</name>
      <address>
        <city>Bad Ems</city>
        <zip>56130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE49103</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE49117</name>
      <address>
        <city>Hagenow</city>
        <zip>19230</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE49105</name>
      <address>
        <city>Hettstedt</city>
        <zip>06333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE49108</name>
      <address>
        <city>Leipzig</city>
        <zip>04105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE49110</name>
      <address>
        <city>Neustadt i. Sachsen</city>
        <zip>01844</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE49118</name>
      <address>
        <city>Reutlingen</city>
        <zip>72764</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE49101</name>
      <address>
        <city>Rostock</city>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE49111</name>
      <address>
        <city>Sangerhausen</city>
        <zip>06526</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE49104</name>
      <address>
        <city>Wismar</city>
        <zip>23970</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HU36108</name>
      <address>
        <city>Csongrád</city>
        <zip>6640</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HU36101</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HU36106</name>
      <address>
        <city>Körmend</city>
        <zip>9900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HU36110</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HU36104</name>
      <address>
        <city>Sopron</city>
        <zip>9400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HU36103</name>
      <address>
        <city>Szekszárd</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HU36107</name>
      <address>
        <city>Tatabánya</city>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT39103</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT39101</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT39105</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT39102</name>
      <address>
        <city>Treviglio (BG)</city>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NL31104</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NL31106</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NL31102</name>
      <address>
        <city>Sneek</city>
        <zip>8601 ZK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NL31101</name>
      <address>
        <city>Winterswijk</city>
        <zip>7101 BN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NO47104</name>
      <address>
        <city>Elverum</city>
        <zip>2408</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NO47102</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL48107</name>
      <address>
        <city>Krakow</city>
        <zip>31-530</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL48103</name>
      <address>
        <city>Lodz</city>
        <zip>90-602</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL48108</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL48106</name>
      <address>
        <city>Piaseczno</city>
        <zip>05-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL48104</name>
      <address>
        <city>Pulawy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL48101</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL48105</name>
      <address>
        <city>Warsaw</city>
        <zip>02-929</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL48112</name>
      <address>
        <city>Wiecbork</city>
        <zip>89-410</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL48111</name>
      <address>
        <city>Wroclaw</city>
        <zip>01-432</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PT35102</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PT35105</name>
      <address>
        <city>Coimbra</city>
        <zip>3041-801</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PT35104</name>
      <address>
        <city>Lisbon</city>
        <zip>1050-199</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PT35107</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PT35110</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PT35101</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PT35106</name>
      <address>
        <city>Tomar</city>
        <zip>2304-909</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RO40106</name>
      <address>
        <city>Brasov</city>
        <zip>500152</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RO40102</name>
      <address>
        <city>Bucharest</city>
        <zip>042122</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RO40104</name>
      <address>
        <city>Bucharest</city>
        <zip>050659</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RO40103</name>
      <address>
        <city>Bucharest</city>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RO40108</name>
      <address>
        <city>Bucharest</city>
        <zip>22328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RO40101</name>
      <address>
        <city>Craiova</city>
        <zip>20116</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RO40105</name>
      <address>
        <city>Craiova</city>
        <zip>20116</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RO40107</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU70112</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU70108</name>
      <address>
        <city>Moscow</city>
        <zip>105425</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU70110</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU70102</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU70103</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194178</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU70101</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197136</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU70107</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU70106</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU70109</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU70113</name>
      <address>
        <city>Ufa</city>
        <zip>450096</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK42109</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK42112</name>
      <address>
        <city>Bratislava</city>
        <zip>832 63</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK42107</name>
      <address>
        <city>Kosice</city>
        <zip>04011</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK42113</name>
      <address>
        <city>Malacky</city>
        <zip>90101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK42104</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK42106</name>
      <address>
        <city>Piestany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK42105</name>
      <address>
        <city>Pieštany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK42102</name>
      <address>
        <city>Presov</city>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK42108</name>
      <address>
        <city>Trencin</city>
        <zip>911 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK42101</name>
      <address>
        <city>Trenčín</city>
        <zip>91101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK42103</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES34103</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES34101</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES34109</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES34102</name>
      <address>
        <city>Madrid</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES34105</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES34104</name>
      <address>
        <city>San Juan de Alicante</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES34107</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE46101</name>
      <address>
        <city>Gothenburg</city>
        <zip>41263</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE46103</name>
      <address>
        <city>Karlshamn</city>
        <zip>37435</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE46104</name>
      <address>
        <city>Malmo</city>
        <zip>21152</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE46102</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE46105</name>
      <address>
        <city>Tanumshede</city>
        <zip>45781</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA38104</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA38102</name>
      <address>
        <city>Donetsk</city>
        <zip>83003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA38111</name>
      <address>
        <city>Donetsk</city>
        <zip>83114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA38106</name>
      <address>
        <city>Kiev</city>
        <zip>01023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA38109</name>
      <address>
        <city>Kiev</city>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA38107</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA38101</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA38103</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB44103</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB44108</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB44106</name>
      <address>
        <city>Garston</city>
        <zip>WD25 0EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB44111</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0XA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB44104</name>
      <address>
        <city>Nantwich</city>
        <zip>CW5 5NX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB44110</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB44107</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB44101</name>
      <address>
        <city>Reading</city>
        <zip>RG1 5AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB44105</name>
      <address>
        <city>Sandbach</city>
        <zip>CW11 1EQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2011</study_first_posted>
  <results_first_submitted>June 23, 2015</results_first_submitted>
  <results_first_submitted_qc>June 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2015</results_first_posted>
  <disposition_first_submitted>June 17, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>June 17, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 25, 2013</disposition_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive bladder (OAB)</keyword>
  <keyword>Frequency</keyword>
  <keyword>Micturition</keyword>
  <keyword>Urgency</keyword>
  <keyword>Urinary incontinence</keyword>
  <keyword>Urgency incontinence</keyword>
  <keyword>YM178</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Urinary Bladder Diseases</mesh_term>
    <mesh_term>Urological Manifestations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Male and female patients with symptoms of overactive bladder (OAB; urgency, urinary frequency and/or urgency incontinence) for at least 3 months. The study was conducted at 141 sites in 20 countries in Europe.</recruitment_details>
      <pre_assignment_details>After screening, 1658 participants entered a 2-week, single-blind, placebo run-in period. After completion of the run-in period, 1307 participants were randomly assigned to 1 of the 12 treatment arms in a 1:1:1:1:2:1:2:2:2:2:1:1 ratio.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Mirabegron 25 mg</title>
          <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Mirabegron 50 mg</title>
          <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Solifenacin 2.5 mg</title>
          <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Solifenacin 5 mg</title>
          <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Solifenacin 10 mg</title>
          <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
          <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
          <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="P9">
          <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
          <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="P10">
          <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
          <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="P11">
          <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
          <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="P12">
          <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
          <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="79"/>
                <participants group_id="P5" count="156"/>
                <participants group_id="P6" count="78"/>
                <participants group_id="P7" count="149"/>
                <participants group_id="P8" count="149"/>
                <participants group_id="P9" count="144"/>
                <participants group_id="P10" count="152"/>
                <participants group_id="P11" count="81"/>
                <participants group_id="P12" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="79"/>
                <participants group_id="P5" count="156"/>
                <participants group_id="P6" count="78"/>
                <participants group_id="P7" count="149"/>
                <participants group_id="P8" count="149"/>
                <participants group_id="P9" count="144"/>
                <participants group_id="P10" count="152"/>
                <participants group_id="P11" count="81"/>
                <participants group_id="P12" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="75"/>
                <participants group_id="P5" count="146"/>
                <participants group_id="P6" count="74"/>
                <participants group_id="P7" count="142"/>
                <participants group_id="P8" count="142"/>
                <participants group_id="P9" count="136"/>
                <participants group_id="P10" count="146"/>
                <participants group_id="P11" count="79"/>
                <participants group_id="P12" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but Never Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Measure data are provided for all randomized patients who took at least 1 dose of double-blind study drug (Safety Analysis Set). One participant randomized to the Mirabegron 25 mg arm received treatment with Solifenacin 5 mg + Mirabegron 50 mg in error and is counted in that arm for safety analysis set analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Mirabegron 25 mg</title>
          <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Mirabegron 50 mg</title>
          <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Solifenacin 2.5 mg</title>
          <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Solifenacin 5 mg</title>
          <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Solifenacin 10 mg</title>
          <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Solifenacin 2.5 mg +Mirabegron 25 mg</title>
          <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
          <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B9">
          <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
          <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B10">
          <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
          <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B11">
          <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
          <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B12">
          <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
          <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="78"/>
            <count group_id="B4" value="79"/>
            <count group_id="B5" value="156"/>
            <count group_id="B6" value="78"/>
            <count group_id="B7" value="149"/>
            <count group_id="B8" value="149"/>
            <count group_id="B9" value="144"/>
            <count group_id="B10" value="153"/>
            <count group_id="B11" value="81"/>
            <count group_id="B12" value="81"/>
            <count group_id="B13" value="1306"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="13.37"/>
                    <measurement group_id="B2" value="55.2" spread="14.45"/>
                    <measurement group_id="B3" value="53.4" spread="13.98"/>
                    <measurement group_id="B4" value="56.1" spread="11.71"/>
                    <measurement group_id="B5" value="54.2" spread="15.53"/>
                    <measurement group_id="B6" value="55.0" spread="12.82"/>
                    <measurement group_id="B7" value="55.8" spread="13.82"/>
                    <measurement group_id="B8" value="53.7" spread="14.55"/>
                    <measurement group_id="B9" value="55.0" spread="14.57"/>
                    <measurement group_id="B10" value="54.1" spread="14.09"/>
                    <measurement group_id="B11" value="56.5" spread="12.34"/>
                    <measurement group_id="B12" value="55.5" spread="13.82"/>
                    <measurement group_id="B13" value="54.8" spread="13.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="103"/>
                    <measurement group_id="B6" value="53"/>
                    <measurement group_id="B7" value="100"/>
                    <measurement group_id="B8" value="100"/>
                    <measurement group_id="B9" value="95"/>
                    <measurement group_id="B10" value="101"/>
                    <measurement group_id="B11" value="52"/>
                    <measurement group_id="B12" value="54"/>
                    <measurement group_id="B13" value="867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="49"/>
                    <measurement group_id="B8" value="49"/>
                    <measurement group_id="B9" value="49"/>
                    <measurement group_id="B10" value="52"/>
                    <measurement group_id="B11" value="29"/>
                    <measurement group_id="B12" value="27"/>
                    <measurement group_id="B13" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="156"/>
                    <measurement group_id="B6" value="77"/>
                    <measurement group_id="B7" value="149"/>
                    <measurement group_id="B8" value="148"/>
                    <measurement group_id="B9" value="143"/>
                    <measurement group_id="B10" value="153"/>
                    <measurement group_id="B11" value="81"/>
                    <measurement group_id="B12" value="81"/>
                    <measurement group_id="B13" value="1302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Overactive Bladder (OAB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Urge Incontinence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="42"/>
                    <measurement group_id="B8" value="33"/>
                    <measurement group_id="B9" value="35"/>
                    <measurement group_id="B10" value="35"/>
                    <measurement group_id="B11" value="23"/>
                    <measurement group_id="B12" value="20"/>
                    <measurement group_id="B13" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="22"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="19"/>
                    <measurement group_id="B10" value="18"/>
                    <measurement group_id="B11" value="14"/>
                    <measurement group_id="B12" value="10"/>
                    <measurement group_id="B13" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="89"/>
                    <measurement group_id="B6" value="48"/>
                    <measurement group_id="B7" value="84"/>
                    <measurement group_id="B8" value="95"/>
                    <measurement group_id="B9" value="90"/>
                    <measurement group_id="B10" value="100"/>
                    <measurement group_id="B11" value="44"/>
                    <measurement group_id="B12" value="50"/>
                    <measurement group_id="B13" value="793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of OAB Symptoms</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.3" spread="38.37"/>
                    <measurement group_id="B2" value="61.2" spread="68.03"/>
                    <measurement group_id="B3" value="56.9" spread="66.62"/>
                    <measurement group_id="B4" value="60.2" spread="67.85"/>
                    <measurement group_id="B5" value="61.8" spread="78.21"/>
                    <measurement group_id="B6" value="52.4" spread="56.98"/>
                    <measurement group_id="B7" value="57.7" spread="68.91"/>
                    <measurement group_id="B8" value="57.0" spread="66.85"/>
                    <measurement group_id="B9" value="56.3" spread="84.78"/>
                    <measurement group_id="B10" value="57.4" spread="81.53"/>
                    <measurement group_id="B11" value="64.9" spread="100.57"/>
                    <measurement group_id="B12" value="57.4" spread="80.12"/>
                    <measurement group_id="B13" value="57.8" spread="73.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Number of Micturitions per 24 Hours</title>
          <description>The average number of micturitions (urinations) a day recorded by the participant in a micturition diary for 3 days prior to the Baseline visit. Data available for 81, 76, 78, 79, 155, 78, 149, 148, 144, 152, 81 and 81 participants in each treatment arm respectively.</description>
          <units>micturitions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.36" spread="2.036"/>
                    <measurement group_id="B2" value="11.29" spread="2.581"/>
                    <measurement group_id="B3" value="10.78" spread="2.254"/>
                    <measurement group_id="B4" value="11.10" spread="3.056"/>
                    <measurement group_id="B5" value="11.34" spread="3.158"/>
                    <measurement group_id="B6" value="11.29" spread="2.896"/>
                    <measurement group_id="B7" value="11.25" spread="3.643"/>
                    <measurement group_id="B8" value="11.00" spread="2.260"/>
                    <measurement group_id="B9" value="10.92" spread="2.386"/>
                    <measurement group_id="B10" value="11.25" spread="3.171"/>
                    <measurement group_id="B11" value="11.14" spread="2.268"/>
                    <measurement group_id="B12" value="11.24" spread="2.453"/>
                    <measurement group_id="B13" value="11.10" spread="2.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Volume Voided per Micturition</title>
          <description>Recorded by the patient in a micturition diary for 3 days prior to the Baseline visit. Data available for 81, 76, 78, 79, 155, 78, 149, 148, 144, 152, 81 and 81 participants in each treatment arm respectively.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156.4" spread="52.80"/>
                    <measurement group_id="B2" value="152.7" spread="56.70"/>
                    <measurement group_id="B3" value="156.8" spread="52.33"/>
                    <measurement group_id="B4" value="162.4" spread="57.59"/>
                    <measurement group_id="B5" value="145.5" spread="59.34"/>
                    <measurement group_id="B6" value="148.0" spread="52.74"/>
                    <measurement group_id="B7" value="156.8" spread="61.97"/>
                    <measurement group_id="B8" value="149.8" spread="50.05"/>
                    <measurement group_id="B9" value="155.0" spread="55.55"/>
                    <measurement group_id="B10" value="153.1" spread="51.88"/>
                    <measurement group_id="B11" value="141.4" spread="51.29"/>
                    <measurement group_id="B12" value="155.3" spread="62.13"/>
                    <measurement group_id="B13" value="152.5" spread="55.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Number of Urgency Episodes per 24 Hours</title>
          <description>Urgency episodes were those classified by the participant in a 3-day micturition diary as 3 or 4 on the Patient Perception of Intensity of Urgency (PPIUS) scale: 0: No urgency; 1: Mild urgency; 2: Moderate urgency, could delay voiding a short while; 3: Severe urgency, could not delay voiding; 4: Urge incontinence, leaked before arriving to the toilet. Data available for 81, 76, 78, 79, 155, 78, 149, 148, 144, 152, 81 and 81 participants in each treatment arm respectively.</description>
          <units>urgency episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.26" spread="3.079"/>
                    <measurement group_id="B2" value="6.25" spread="3.332"/>
                    <measurement group_id="B3" value="6.58" spread="3.981"/>
                    <measurement group_id="B4" value="6.20" spread="3.870"/>
                    <measurement group_id="B5" value="6.41" spread="4.154"/>
                    <measurement group_id="B6" value="6.37" spread="4.530"/>
                    <measurement group_id="B7" value="6.05" spread="3.749"/>
                    <measurement group_id="B8" value="6.78" spread="3.419"/>
                    <measurement group_id="B9" value="6.26" spread="3.928"/>
                    <measurement group_id="B10" value="6.49" spread="4.238"/>
                    <measurement group_id="B11" value="6.91" spread="4.319"/>
                    <measurement group_id="B12" value="6.81" spread="4.312"/>
                    <measurement group_id="B13" value="6.37" spread="3.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Level of Urgency</title>
          <description>Average of participants’ ratings on the degree of associated urgency for each micturition and/or incontinence episode recorded in a 3-day micturition diary according to the following 5-point categorical scale (Patient Perception of Intensity of Urgency Scale): 0: No urgency; 1: Mild urgency; 2: Moderate urgency, could delay voiding a short while; 3: Severe urgency, could not delay voiding; 4: Urge incontinence, leaked before arriving to the toilet. Data available for 81, 76, 78, 79, 155, 78, 149, 148, 144, 152, 81 and 81 participants in each treatment arm respectively.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.45" spread="0.503"/>
                    <measurement group_id="B2" value="2.53" spread="0.439"/>
                    <measurement group_id="B3" value="2.55" spread="0.508"/>
                    <measurement group_id="B4" value="2.53" spread="0.539"/>
                    <measurement group_id="B5" value="2.49" spread="0.508"/>
                    <measurement group_id="B6" value="2.48" spread="0.503"/>
                    <measurement group_id="B7" value="2.49" spread="0.445"/>
                    <measurement group_id="B8" value="2.59" spread="0.446"/>
                    <measurement group_id="B9" value="2.50" spread="0.491"/>
                    <measurement group_id="B10" value="2.51" spread="0.441"/>
                    <measurement group_id="B11" value="2.57" spread="0.493"/>
                    <measurement group_id="B12" value="2.53" spread="0.473"/>
                    <measurement group_id="B13" value="2.52" spread="0.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Number of Nocturia Episodes per 24 Hours</title>
          <description>The average number of times a participant woke at night to urinate (excluding incontinence only episodes) recorded for 3 days prior to the Baseline visit in the patient micturition diary. Data available for 81, 76, 78, 79, 155, 78, 149, 148, 144, 152, 81 and 81 participants in each treatment arm respectively.</description>
          <units>nocturia episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.19" spread="1.584"/>
                    <measurement group_id="B2" value="2.18" spread="1.392"/>
                    <measurement group_id="B3" value="2.31" spread="1.517"/>
                    <measurement group_id="B4" value="2.46" spread="1.852"/>
                    <measurement group_id="B5" value="2.19" spread="1.399"/>
                    <measurement group_id="B6" value="2.50" spread="1.859"/>
                    <measurement group_id="B7" value="2.64" spread="2.259"/>
                    <measurement group_id="B8" value="2.05" spread="1.219"/>
                    <measurement group_id="B9" value="2.28" spread="1.449"/>
                    <measurement group_id="B10" value="2.27" spread="1.305"/>
                    <measurement group_id="B11" value="2.65" spread="2.525"/>
                    <measurement group_id="B12" value="2.41" spread="2.001"/>
                    <measurement group_id="B13" value="2.33" spread="1.701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Number of Incontinence Episodes per 24 Hours</title>
          <description>The average number of incontinence episodes (any involuntary leakage of urine) a day recorded by the participant in a micturition diary for 3 days prior to the Baseline visit. Data are reported for participants who took at least 1 dose of double-blind study medication with available primary efficacy data who reported at least 1 incontinence episode in the Baseline diary (Full Analysis Set-Incontinence): 17, 13, 18, 15, 35, 15, 35, 33, 32, 24, 24, 20 participants in each treatment arm respectively.</description>
          <units>incontinence episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.95" spread="0.765"/>
                    <measurement group_id="B2" value="1.87" spread="1.578"/>
                    <measurement group_id="B3" value="1.26" spread="1.000"/>
                    <measurement group_id="B4" value="1.80" spread="1.167"/>
                    <measurement group_id="B5" value="1.33" spread="1.242"/>
                    <measurement group_id="B6" value="1.40" spread="1.280"/>
                    <measurement group_id="B7" value="1.27" spread="1.096"/>
                    <measurement group_id="B8" value="1.14" spread="0.791"/>
                    <measurement group_id="B9" value="1.24" spread="1.108"/>
                    <measurement group_id="B10" value="1.17" spread="1.196"/>
                    <measurement group_id="B11" value="1.53" spread="1.235"/>
                    <measurement group_id="B12" value="1.25" spread="0.858"/>
                    <measurement group_id="B13" value="1.31" spread="1.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Number of Urgency Incontinence Episodes per 24 Hours</title>
          <description>The average number of urgency incontinence episodes (involuntary urine leakage accompanied by or immediately preceded by urgency) a day recorded by the participant in a micturition diary for 3 days prior to the Baseline visit. Data are reported for participants who took at least 1 dose of double-blind study medication with available primary efficacy data who reported at least 1 incontinence episode in the Baseline diary (Full Analysis Set-Incontinence): 17, 13, 18, 15, 35, 15, 35, 33, 32, 24, 24, and 20 participants in each treatment arm respectively.</description>
          <units>urgency incontinence episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.78" spread="0.807"/>
                    <measurement group_id="B2" value="1.54" spread="1.337"/>
                    <measurement group_id="B3" value="1.19" spread="1.043"/>
                    <measurement group_id="B4" value="1.56" spread="1.052"/>
                    <measurement group_id="B5" value="1.32" spread="1.227"/>
                    <measurement group_id="B6" value="1.18" spread="1.308"/>
                    <measurement group_id="B7" value="0.96" spread="0.903"/>
                    <measurement group_id="B8" value="1.06" spread="0.757"/>
                    <measurement group_id="B9" value="1.23" spread="1.118"/>
                    <measurement group_id="B10" value="1.08" spread="1.193"/>
                    <measurement group_id="B11" value="1.51" spread="1.247"/>
                    <measurement group_id="B12" value="1.20" spread="0.901"/>
                    <measurement group_id="B13" value="1.20" spread="1.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Treatment (EOT) in Mean Volume Voided Per Micturition</title>
        <description>The average volume voided per micturition was calculated from the volume of each micturition measured by the participant and recorded in a micturition diary for 3 days before the Baseline and Week 12 clinic visits.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The Full Analysis Set (FAS) comprised all participants took at least 1 dose of double-blind study medication after randomization and had primary efficacy data (mean volume voided) derived from the diary at Baseline and at least 1 post-baseline visit. Last observation carried forward imputation (LOCF) was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment (EOT) in Mean Volume Voided Per Micturition</title>
          <description>The average volume voided per micturition was calculated from the volume of each micturition measured by the participant and recorded in a micturition diary for 3 days before the Baseline and Week 12 clinic visits.</description>
          <population>The Full Analysis Set (FAS) comprised all participants took at least 1 dose of double-blind study medication after randomization and had primary efficacy data (mean volume voided) derived from the diary at Baseline and at least 1 post-baseline visit. Last observation carried forward imputation (LOCF) was utilized.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="5.91"/>
                    <measurement group_id="O2" value="24.9" spread="6.06"/>
                    <measurement group_id="O3" value="34.5" spread="6.02"/>
                    <measurement group_id="O4" value="36.4" spread="6.02"/>
                    <measurement group_id="O5" value="36.0" spread="4.32"/>
                    <measurement group_id="O6" value="36.2" spread="6.06"/>
                    <measurement group_id="O7" value="39.4" spread="4.37"/>
                    <measurement group_id="O8" value="41.9" spread="4.36"/>
                    <measurement group_id="O9" value="53.6" spread="4.45"/>
                    <measurement group_id="O10" value="54.2" spread="4.31"/>
                    <measurement group_id="O11" value="57.6" spread="5.99"/>
                    <measurement group_id="O12" value="62.3" spread="5.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Statistical comparisons were made using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The ANCOVA model for all pairwise comparisons includes the 2 main factors mirabegron dose and solifenacin succinate dose and their interaction, sex, age group and geographic region as fixed factors and Baseline value as a covariate.
Least squares (LS) mean differences were calculated by subtracting Solifenacin 5 mg/Placebo from the comparison treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.3</ci_lower_limit>
            <ci_upper_limit>14.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.6</ci_lower_limit>
            <ci_upper_limit>15.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.1</ci_lower_limit>
            <ci_upper_limit>18.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>17.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.4</ci_lower_limit>
            <ci_upper_limit>29.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>18.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.2</ci_lower_limit>
            <ci_upper_limit>30.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>21.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.2</ci_lower_limit>
            <ci_upper_limit>36.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>26.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.9</ci_lower_limit>
            <ci_upper_limit>40.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>11.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>27.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>20.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.0</ci_lower_limit>
            <ci_upper_limit>37.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>22.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.9</ci_lower_limit>
            <ci_upper_limit>39.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>22.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.6</ci_lower_limit>
            <ci_upper_limit>36.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>22.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.6</ci_lower_limit>
            <ci_upper_limit>38.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>25.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.0</ci_lower_limit>
            <ci_upper_limit>39.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>27.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.5</ci_lower_limit>
            <ci_upper_limit>42.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>39.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.1</ci_lower_limit>
            <ci_upper_limit>54.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean DIfference</param_type>
            <param_value>40.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.8</ci_lower_limit>
            <ci_upper_limit>54.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>43.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.1</ci_lower_limit>
            <ci_upper_limit>60.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>48.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.9</ci_lower_limit>
            <ci_upper_limit>64.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours</title>
        <description>The average number of micturitions (urinations) per 24 hours was derived from the number of urinations (excluding incontinence only episodes) per day recorded by the participant in the micturition diary for 3-days before the Baseline and Week 12 clinic visits.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours</title>
          <description>The average number of micturitions (urinations) per 24 hours was derived from the number of urinations (excluding incontinence only episodes) per day recorded by the participant in the micturition diary for 3-days before the Baseline and Week 12 clinic visits.</description>
          <population>Full analysis set; LOCF was used.</population>
          <units>micturitions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.43" spread="0.291"/>
                    <measurement group_id="O2" value="-2.48" spread="0.298"/>
                    <measurement group_id="O3" value="-2.56" spread="0.296"/>
                    <measurement group_id="O4" value="-2.44" spread="0.296"/>
                    <measurement group_id="O5" value="-2.54" spread="0.212"/>
                    <measurement group_id="O6" value="-3.22" spread="0.298"/>
                    <measurement group_id="O7" value="-2.58" spread="0.215"/>
                    <measurement group_id="O8" value="-2.93" spread="0.215"/>
                    <measurement group_id="O9" value="-2.56" spread="0.219"/>
                    <measurement group_id="O10" value="-3.34" spread="0.212"/>
                    <measurement group_id="O11" value="-3.42" spread="0.294"/>
                    <measurement group_id="O12" value="-3.52" spread="0.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Statistical comparisons were made using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The ANCOVA model for all pairwise comparisons includes the 2 main factors mirabegron dose and solifenacin succinate dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.
LS Mean Differences were calculated by subtracting Solifenacin 5 mg/Placebo from the comparison treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.366</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.40</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.302</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.302</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.98</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.305</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.300</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.363</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.59</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.360</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.68</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.417</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.415</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.416</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.361</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.417</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.362</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.362</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.364</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.361</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.62</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.414</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.80</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.412</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.89</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours</title>
        <description>The average number of incontinence episodes (any involuntary leakage of urine) per day was derived from the number of incontinence episodes recorded by the participant in the micturition diary for 3-days before the Baseline and Week 12 clinic visits.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The Full Analysis Set-Incontinence comprised participants in the FAS who reported at least 1 incontinence episode in the baseline diary. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours</title>
          <description>The average number of incontinence episodes (any involuntary leakage of urine) per day was derived from the number of incontinence episodes recorded by the participant in the micturition diary for 3-days before the Baseline and Week 12 clinic visits.</description>
          <population>The Full Analysis Set-Incontinence comprised participants in the FAS who reported at least 1 incontinence episode in the baseline diary. LOCF was used.</population>
          <units>incontinence episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="32"/>
                <count group_id="O10" value="24"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="0.365"/>
                    <measurement group_id="O2" value="-0.74" spread="0.415"/>
                    <measurement group_id="O3" value="-0.90" spread="0.353"/>
                    <measurement group_id="O4" value="-1.26" spread="0.386"/>
                    <measurement group_id="O5" value="-0.88" spread="0.252"/>
                    <measurement group_id="O6" value="-0.97" spread="0.386"/>
                    <measurement group_id="O7" value="-0.75" spread="0.251"/>
                    <measurement group_id="O8" value="-0.85" spread="0.260"/>
                    <measurement group_id="O9" value="-1.22" spread="0.266"/>
                    <measurement group_id="O10" value="-1.14" spread="0.306"/>
                    <measurement group_id="O11" value="-0.27" spread="0.304"/>
                    <measurement group_id="O12" value="-0.97" spread="0.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The ANCOVA model including the 2 main factors mirabegron dose and solifenacin dose and their interaction, sex, age group and geographic region as fixed factors and Baseline measurement as a covariate was used to calculate point estimates and 95% confidence intervals (CI) for change from Baseline within each treatment group and for differences between combination treatment groups and solifenacin 5 mg as well as for differences between active treatment groups and placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <p_value_desc>Statistical comparisons were made using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.</p_value_desc>
            <method>Stratified Rank ANCOVA</method>
            <method_desc>P-values are from pairwise comparisons of the combination/active treatment groups vs. solifenacin 5 mg/placebo within a stratified rank ANCOVA model.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.460</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.355</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.361</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P values were calculated from a pairwise comparison of the combination treatment groups vs solifenacin succinate 5 mg or placebo within the ANCOVA model.</p_value_desc>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.365</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.06</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.397</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.395</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.417</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.554</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.505</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.95</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.533</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.36</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.444</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.534</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.443</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.448</dispersion_value>
            <ci_percent>2</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.78</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.454</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.472</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.475</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.494</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Visit in Mean Volume Voided Per Micturition</title>
        <description>The average volume voided per micturition was calculated from the volume of each micturition measured by the participant and recorded in a micturition diary for 3 days before the Baseline and each post-baseline clinic visit.</description>
        <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
        <population>Full analysis set including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;)..</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each Visit in Mean Volume Voided Per Micturition</title>
          <description>The average volume voided per micturition was calculated from the volume of each micturition measured by the participant and recorded in a micturition diary for 3 days before the Baseline and each post-baseline clinic visit.</description>
          <population>Full analysis set including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;)..</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2; n=80,71,76,74,148,73,145,145,136,141,76,77</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="4.44"/>
                    <measurement group_id="O2" value="14.3" spread="4.71"/>
                    <measurement group_id="O3" value="26.0" spread="4.55"/>
                    <measurement group_id="O4" value="22.7" spread="4.62"/>
                    <measurement group_id="O5" value="23.1" spread="3.26"/>
                    <measurement group_id="O6" value="16.1" spread="4.64"/>
                    <measurement group_id="O7" value="22.5" spread="3.30"/>
                    <measurement group_id="O8" value="29.2" spread="3.30"/>
                    <measurement group_id="O9" value="29.9" spread="3.40"/>
                    <measurement group_id="O10" value="32.3" spread="3.34"/>
                    <measurement group_id="O11" value="29.5" spread="4.56"/>
                    <measurement group_id="O12" value="42.1" spread="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; n=79,72,74,76,146,72,141,142,138,144,77,75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="4.93"/>
                    <measurement group_id="O2" value="16.8" spread="5.16"/>
                    <measurement group_id="O3" value="29.4" spread="5.09"/>
                    <measurement group_id="O4" value="24.8" spread="5.02"/>
                    <measurement group_id="O5" value="29.6" spread="3.63"/>
                    <measurement group_id="O6" value="28.3" spread="5.16"/>
                    <measurement group_id="O7" value="29.2" spread="3.69"/>
                    <measurement group_id="O8" value="36.5" spread="3.67"/>
                    <measurement group_id="O9" value="42.7" spread="3.73"/>
                    <measurement group_id="O10" value="44.5" spread="3.65"/>
                    <measurement group_id="O11" value="45.7" spread="5.00"/>
                    <measurement group_id="O12" value="54.5" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8; n=77,70,73,75,147,73,143,142,134,143,76,74</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="5.56"/>
                    <measurement group_id="O2" value="24.6" spread="5.83"/>
                    <measurement group_id="O3" value="35.4" spread="5.71"/>
                    <measurement group_id="O4" value="28.3" spread="5.63"/>
                    <measurement group_id="O5" value="30.1" spread="4.03"/>
                    <measurement group_id="O6" value="37.7" spread="5.71"/>
                    <measurement group_id="O7" value="35.6" spread="4.08"/>
                    <measurement group_id="O8" value="42.3" spread="4.09"/>
                    <measurement group_id="O9" value="49.7" spread="4.21"/>
                    <measurement group_id="O10" value="52.2" spread="4.08"/>
                    <measurement group_id="O11" value="55.8" spread="5.60"/>
                    <measurement group_id="O12" value="68.5" spread="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12;n=75,68,73,73,144,72,138,138,133,140,72,73</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="6.12"/>
                    <measurement group_id="O2" value="23.0" spread="6.43"/>
                    <measurement group_id="O3" value="35.5" spread="6.20"/>
                    <measurement group_id="O4" value="36.9" spread="6.20"/>
                    <measurement group_id="O5" value="34.6" spread="4.42"/>
                    <measurement group_id="O6" value="35.8" spread="6.25"/>
                    <measurement group_id="O7" value="38.6" spread="4.52"/>
                    <measurement group_id="O8" value="43.7" spread="4.51"/>
                    <measurement group_id="O9" value="54.7" spread="4.60"/>
                    <measurement group_id="O10" value="56.6" spread="4.48"/>
                    <measurement group_id="O11" value="59.8" spread="6.26"/>
                    <measurement group_id="O12" value="66.2" spread="6.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Visit in Mean Number of Micturitions Per 24 Hours</title>
        <description>The average number of micturitions (urinations) per 24 hours was derived from the number of urinations (excluding incontinence only episodes) per day recorded by the participant in the micturition diary for 3-days before the Baseline and each post-baseline clinic visit.</description>
        <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
        <population>Full analysis set including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each Visit in Mean Number of Micturitions Per 24 Hours</title>
          <description>The average number of micturitions (urinations) per 24 hours was derived from the number of urinations (excluding incontinence only episodes) per day recorded by the participant in the micturition diary for 3-days before the Baseline and each post-baseline clinic visit.</description>
          <population>Full analysis set including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;).</population>
          <units>micturitions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2; n=80,71,76,74,148,73,145,145,136,141,77,77</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="0.240"/>
                    <measurement group_id="O2" value="-1.69" spread="0.255"/>
                    <measurement group_id="O3" value="-1.60" spread="0.246"/>
                    <measurement group_id="O4" value="-1.49" spread="0.249"/>
                    <measurement group_id="O5" value="-1.16" spread="0.176"/>
                    <measurement group_id="O6" value="-1.32" spread="0.251"/>
                    <measurement group_id="O7" value="-1.52" spread="0.178"/>
                    <measurement group_id="O8" value="-1.95" spread="0.178"/>
                    <measurement group_id="O9" value="-1.68" spread="0.184"/>
                    <measurement group_id="O10" value="-2.21" spread="0.181"/>
                    <measurement group_id="O11" value="-1.74" spread="0.244"/>
                    <measurement group_id="O12" value="-2.35" spread="0.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; n=79,72,74,76,147,73,141,142,138,144,77,75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" spread="0.261"/>
                    <measurement group_id="O2" value="-2.02" spread="0.273"/>
                    <measurement group_id="O3" value="-1.99" spread="0.269"/>
                    <measurement group_id="O4" value="-2.10" spread="0.266"/>
                    <measurement group_id="O5" value="-1.80" spread="0.191"/>
                    <measurement group_id="O6" value="-2.25" spread="0.271"/>
                    <measurement group_id="O7" value="-2.03" spread="0.195"/>
                    <measurement group_id="O8" value="-2.11" spread="0.194"/>
                    <measurement group_id="O9" value="-2.29" spread="0.197"/>
                    <measurement group_id="O10" value="-2.77" spread="0.193"/>
                    <measurement group_id="O11" value="-2.55" spread="0.264"/>
                    <measurement group_id="O12" value="-2.69" spread="0.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8; n=77,70,73,75,147,74,143,142,134,145,77,74</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" spread="0.270"/>
                    <measurement group_id="O2" value="-2.27" spread="0.283"/>
                    <measurement group_id="O3" value="-2.42" spread="0.277"/>
                    <measurement group_id="O4" value="-2.46" spread="0.273"/>
                    <measurement group_id="O5" value="-2.22" spread="0.196"/>
                    <measurement group_id="O6" value="-2.97" spread="0.275"/>
                    <measurement group_id="O7" value="-2.58" spread="0.198"/>
                    <measurement group_id="O8" value="-2.66" spread="0.199"/>
                    <measurement group_id="O9" value="-2.43" spread="0.205"/>
                    <measurement group_id="O10" value="-3.20" spread="0.197"/>
                    <measurement group_id="O11" value="-3.04" spread="0.270"/>
                    <measurement group_id="O12" value="-3.49" spread="0.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12;n=75,69,73,73,144,73,138,138,133,144,75,73</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.59" spread="0.302"/>
                    <measurement group_id="O2" value="-2.51" spread="0.314"/>
                    <measurement group_id="O3" value="-2.67" spread="0.306"/>
                    <measurement group_id="O4" value="-2.38" spread="0.306"/>
                    <measurement group_id="O5" value="-2.58" spread="0.218"/>
                    <measurement group_id="O6" value="-3.31" spread="0.306"/>
                    <measurement group_id="O7" value="-2.64" spread="0.222"/>
                    <measurement group_id="O8" value="-3.02" spread="0.222"/>
                    <measurement group_id="O9" value="-2.64" spread="0.227"/>
                    <measurement group_id="O10" value="-3.35" spread="0.218"/>
                    <measurement group_id="O11" value="-3.47" spread="0.302"/>
                    <measurement group_id="O12" value="-3.63" spread="0.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Micturition Response</title>
        <description>A responder is defined as a participant with at most 8 micturitions per 24 hours post-baseline and a negative change (i.e. an improvement) from Baseline.</description>
        <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
        <population>Full analysis set participants with at least 8 micturitions per 24 hours at Baseline and including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;); LOCF imputation was used for the End of Treatment (EOT) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Micturition Response</title>
          <description>A responder is defined as a participant with at most 8 micturitions per 24 hours post-baseline and a negative change (i.e. an improvement) from Baseline.</description>
          <population>Full analysis set participants with at least 8 micturitions per 24 hours at Baseline and including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;); LOCF imputation was used for the End of Treatment (EOT) analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2; n=79,70,75,71,144,72,143,143,135,137,77,76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="25.7"/>
                    <measurement group_id="O3" value="37.3"/>
                    <measurement group_id="O4" value="29.6"/>
                    <measurement group_id="O5" value="26.4"/>
                    <measurement group_id="O6" value="34.7"/>
                    <measurement group_id="O7" value="36.4"/>
                    <measurement group_id="O8" value="38.5"/>
                    <measurement group_id="O9" value="34.1"/>
                    <measurement group_id="O10" value="36.5"/>
                    <measurement group_id="O11" value="36.4"/>
                    <measurement group_id="O12" value="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; n=78,72,73,73,144,72,139,140,137,140,77,74</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3"/>
                    <measurement group_id="O2" value="27.8"/>
                    <measurement group_id="O3" value="43.8"/>
                    <measurement group_id="O4" value="35.6"/>
                    <measurement group_id="O5" value="34.0"/>
                    <measurement group_id="O6" value="44.4"/>
                    <measurement group_id="O7" value="45.3"/>
                    <measurement group_id="O8" value="42.1"/>
                    <measurement group_id="O9" value="48.2"/>
                    <measurement group_id="O10" value="56.4"/>
                    <measurement group_id="O11" value="48.1"/>
                    <measurement group_id="O12" value="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8; n=76,70,73,72,145,73,141,140,133,142,77,73</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9"/>
                    <measurement group_id="O2" value="35.7"/>
                    <measurement group_id="O3" value="50.7"/>
                    <measurement group_id="O4" value="43.1"/>
                    <measurement group_id="O5" value="40.0"/>
                    <measurement group_id="O6" value="56.2"/>
                    <measurement group_id="O7" value="46.8"/>
                    <measurement group_id="O8" value="54.3"/>
                    <measurement group_id="O9" value="49.6"/>
                    <measurement group_id="O10" value="56.3"/>
                    <measurement group_id="O11" value="57.1"/>
                    <measurement group_id="O12" value="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12;n=74,69,72,69,142,72,136,136,132,142,75,72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4"/>
                    <measurement group_id="O2" value="46.4"/>
                    <measurement group_id="O3" value="47.2"/>
                    <measurement group_id="O4" value="53.6"/>
                    <measurement group_id="O5" value="47.9"/>
                    <measurement group_id="O6" value="55.6"/>
                    <measurement group_id="O7" value="55.1"/>
                    <measurement group_id="O8" value="55.1"/>
                    <measurement group_id="O9" value="53.8"/>
                    <measurement group_id="O10" value="62.0"/>
                    <measurement group_id="O11" value="65.3"/>
                    <measurement group_id="O12" value="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT; n=79,75,76,73,146,75,144,145,140,146,78,79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2"/>
                    <measurement group_id="O2" value="42.7"/>
                    <measurement group_id="O3" value="47.4"/>
                    <measurement group_id="O4" value="54.8"/>
                    <measurement group_id="O5" value="47.9"/>
                    <measurement group_id="O6" value="54.7"/>
                    <measurement group_id="O7" value="54.2"/>
                    <measurement group_id="O8" value="53.1"/>
                    <measurement group_id="O9" value="52.1"/>
                    <measurement group_id="O10" value="61.6"/>
                    <measurement group_id="O11" value="65.4"/>
                    <measurement group_id="O12" value="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>All statistical comparisons are for End of Treatment using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The logistic regression model includes the 2 main factors mirabegron dose and solifenacin dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>3.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>3.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>2.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>2.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>2.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>3.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.16</ci_lower_limit>
            <ci_upper_limit>4.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>3.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Visit in Mean Number of Incontinence Episodes Per 24 Hours</title>
        <description>The average number of incontinence episodes (any involuntary leakage of urine) per day was derived from the number of incontinence episodes recorded by the participant in the micturition diary for 3-days before the Baseline and each post-baseline clinic visit.</description>
        <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
        <population>Full Analysis Set-Incontinence including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each Visit in Mean Number of Incontinence Episodes Per 24 Hours</title>
          <description>The average number of incontinence episodes (any involuntary leakage of urine) per day was derived from the number of incontinence episodes recorded by the participant in the micturition diary for 3-days before the Baseline and each post-baseline clinic visit.</description>
          <population>Full Analysis Set-Incontinence including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;).</population>
          <units>incontinence episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="32"/>
                <count group_id="O10" value="24"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2; n=17,13,18,15,33,14,35,33,32,21,24,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.168"/>
                    <measurement group_id="O2" value="-0.43" spread="0.191"/>
                    <measurement group_id="O3" value="-0.85" spread="0.162"/>
                    <measurement group_id="O4" value="-0.98" spread="0.178"/>
                    <measurement group_id="O5" value="-0.67" spread="0.119"/>
                    <measurement group_id="O6" value="-0.71" spread="0.184"/>
                    <measurement group_id="O7" value="-0.49" spread="0.116"/>
                    <measurement group_id="O8" value="-0.64" spread="0.120"/>
                    <measurement group_id="O9" value="-0.70" spread="0.122"/>
                    <measurement group_id="O10" value="-0.65" spread="0.150"/>
                    <measurement group_id="O11" value="-1.14" spread="0.140"/>
                    <measurement group_id="O12" value="-0.77" spread="0.157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; n=17,10,18,15,34,14,34,30,32,23,24,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="0.146"/>
                    <measurement group_id="O2" value="-0.48" spread="0.189"/>
                    <measurement group_id="O3" value="-0.89" spread="0.141"/>
                    <measurement group_id="O4" value="-1.20" spread="0.155"/>
                    <measurement group_id="O5" value="-0.80" spread="0.102"/>
                    <measurement group_id="O6" value="-0.84" spread="0.160"/>
                    <measurement group_id="O7" value="-0.73" spread="0.102"/>
                    <measurement group_id="O8" value="-0.67" spread="0.109"/>
                    <measurement group_id="O9" value="-0.81" spread="0.106"/>
                    <measurement group_id="O10" value="-0.88" spread="0.125"/>
                    <measurement group_id="O11" value="-1.18" spread="0.122"/>
                    <measurement group_id="O12" value="-0.71" spread="0.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8; n=17,10,18,14,34,15,35,30,32,22,24,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.163"/>
                    <measurement group_id="O2" value="-0.65" spread="0.210"/>
                    <measurement group_id="O3" value="-0.92" spread="0.157"/>
                    <measurement group_id="O4" value="-1.12" spread="0.178"/>
                    <measurement group_id="O5" value="-0.72" spread="0.114"/>
                    <measurement group_id="O6" value="-1.04" spread="0.172"/>
                    <measurement group_id="O7" value="-0.78" spread="0.112"/>
                    <measurement group_id="O8" value="-0.82" spread="0.122"/>
                    <measurement group_id="O9" value="-1.01" spread="0.118"/>
                    <measurement group_id="O10" value="-0.95" spread="0.142"/>
                    <measurement group_id="O11" value="-0.93" spread="0.136"/>
                    <measurement group_id="O12" value="-0.91" spread="0.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12; n=17,10,18,13,34,14,33,30,30,23,24,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" spread="0.373"/>
                    <measurement group_id="O2" value="-0.59" spread="0.482"/>
                    <measurement group_id="O3" value="-0.89" spread="0.361"/>
                    <measurement group_id="O4" value="-1.21" spread="0.424"/>
                    <measurement group_id="O5" value="-0.84" spread="0.261"/>
                    <measurement group_id="O6" value="-0.95" spread="0.409"/>
                    <measurement group_id="O7" value="-0.74" spread="0.265"/>
                    <measurement group_id="O8" value="-0.88" spread="0.279"/>
                    <measurement group_id="O9" value="-1.20" spread="0.280"/>
                    <measurement group_id="O10" value="-1.11" spread="0.319"/>
                    <measurement group_id="O11" value="-0.27" spread="0.311"/>
                    <measurement group_id="O12" value="-0.96" spread="0.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Zero Incontinence Episodes Post-baseline</title>
        <description>The percentage of participants with no incontinence episodes for the 3 days prior to each clinic visit derived from the micturition diary recorded by the participant.</description>
        <time_frame>Weeks 2, 4, 8 and 12</time_frame>
        <population>Full Analysis Set-Incontinence including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;); LOCF imputation was used for the End of Treatment (EOT) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Zero Incontinence Episodes Post-baseline</title>
          <description>The percentage of participants with no incontinence episodes for the 3 days prior to each clinic visit derived from the micturition diary recorded by the participant.</description>
          <population>Full Analysis Set-Incontinence including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;); LOCF imputation was used for the End of Treatment (EOT) analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="32"/>
                <count group_id="O10" value="24"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2; n=17,13,18,15,33,14,35,33,32,21,24,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="40.0"/>
                    <measurement group_id="O5" value="45.5"/>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="51.5"/>
                    <measurement group_id="O9" value="65.6"/>
                    <measurement group_id="O10" value="52.4"/>
                    <measurement group_id="O11" value="70.8"/>
                    <measurement group_id="O12" value="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; n=17,10,18,15,34,14,34,30,32,23,24,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="73.3"/>
                    <measurement group_id="O5" value="64.7"/>
                    <measurement group_id="O6" value="71.4"/>
                    <measurement group_id="O7" value="55.9"/>
                    <measurement group_id="O8" value="46.7"/>
                    <measurement group_id="O9" value="62.5"/>
                    <measurement group_id="O10" value="52.2"/>
                    <measurement group_id="O11" value="79.2"/>
                    <measurement group_id="O12" value="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8; n=17,10,18,14,34,15,35,30,32,22,24,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="61.1"/>
                    <measurement group_id="O4" value="71.4"/>
                    <measurement group_id="O5" value="50.0"/>
                    <measurement group_id="O6" value="73.3"/>
                    <measurement group_id="O7" value="54.3"/>
                    <measurement group_id="O8" value="50.0"/>
                    <measurement group_id="O9" value="71.9"/>
                    <measurement group_id="O10" value="77.3"/>
                    <measurement group_id="O11" value="79.2"/>
                    <measurement group_id="O12" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12; n=17,10,18,13,34,14,33,30,30,23,24,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="61.1"/>
                    <measurement group_id="O4" value="69.2"/>
                    <measurement group_id="O5" value="58.8"/>
                    <measurement group_id="O6" value="57.1"/>
                    <measurement group_id="O7" value="51.5"/>
                    <measurement group_id="O8" value="63.3"/>
                    <measurement group_id="O9" value="86.7"/>
                    <measurement group_id="O10" value="87.0"/>
                    <measurement group_id="O11" value="79.2"/>
                    <measurement group_id="O12" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT; n=17,13,18,15,35,15,35,33,32,24,24,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4"/>
                    <measurement group_id="O2" value="46.2"/>
                    <measurement group_id="O3" value="61.1"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="60.0"/>
                    <measurement group_id="O6" value="53.3"/>
                    <measurement group_id="O7" value="54.3"/>
                    <measurement group_id="O8" value="60.6"/>
                    <measurement group_id="O9" value="87.5"/>
                    <measurement group_id="O10" value="87.5"/>
                    <measurement group_id="O11" value="79.2"/>
                    <measurement group_id="O12" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>All statistical comparisons are for End of Treatment using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The logistic regression model includes the 2 main factors mirabegron dose and solifenacin dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>1.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>2.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.47</ci_lower_limit>
            <ci_upper_limit>25.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>25.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>15.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>7.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>2.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>6.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>16.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>15.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>9.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>4.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With 50% Reduction in Incontinence Episodes</title>
        <description>The percentage of participants with at least a 50% decrease from Baseline in mean number of incontinence episodes per 24 hours during the 3 days prior to each clinic visit derived from the participant's micturition diary.</description>
        <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
        <population>Full Analysis Set-Incontinence including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;); LOCF imputation was used for the End of Treatment (EOT) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With 50% Reduction in Incontinence Episodes</title>
          <description>The percentage of participants with at least a 50% decrease from Baseline in mean number of incontinence episodes per 24 hours during the 3 days prior to each clinic visit derived from the participant's micturition diary.</description>
          <population>Full Analysis Set-Incontinence including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;); LOCF imputation was used for the End of Treatment (EOT) analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="32"/>
                <count group_id="O10" value="24"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2; n=17,13,18,15,33,14,35,33,32,21,24,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7"/>
                    <measurement group_id="O2" value="30.8"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="73.3"/>
                    <measurement group_id="O5" value="57.6"/>
                    <measurement group_id="O6" value="57.1"/>
                    <measurement group_id="O7" value="51.4"/>
                    <measurement group_id="O8" value="66.7"/>
                    <measurement group_id="O9" value="71.9"/>
                    <measurement group_id="O10" value="66.7"/>
                    <measurement group_id="O11" value="91.7"/>
                    <measurement group_id="O12" value="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; n=17,10,18,15,34,14,34,30,32,23,24,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="72.2"/>
                    <measurement group_id="O4" value="86.7"/>
                    <measurement group_id="O5" value="76.5"/>
                    <measurement group_id="O6" value="78.6"/>
                    <measurement group_id="O7" value="64.7"/>
                    <measurement group_id="O8" value="63.3"/>
                    <measurement group_id="O9" value="75.0"/>
                    <measurement group_id="O10" value="78.3"/>
                    <measurement group_id="O11" value="95.8"/>
                    <measurement group_id="O12" value="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8; n=17,10,18,14,34,15,35,30,32,22,24,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="77.8"/>
                    <measurement group_id="O4" value="85.7"/>
                    <measurement group_id="O5" value="58.8"/>
                    <measurement group_id="O6" value="86.7"/>
                    <measurement group_id="O7" value="82.9"/>
                    <measurement group_id="O8" value="73.3"/>
                    <measurement group_id="O9" value="90.6"/>
                    <measurement group_id="O10" value="81.8"/>
                    <measurement group_id="O11" value="91.7"/>
                    <measurement group_id="O12" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12; n=17,10,18,13,34,14,33,30,30,23,24,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                    <measurement group_id="O2" value="70.0"/>
                    <measurement group_id="O3" value="77.8"/>
                    <measurement group_id="O4" value="84.6"/>
                    <measurement group_id="O5" value="73.5"/>
                    <measurement group_id="O6" value="64.3"/>
                    <measurement group_id="O7" value="66.7"/>
                    <measurement group_id="O8" value="80.0"/>
                    <measurement group_id="O9" value="96.7"/>
                    <measurement group_id="O10" value="95.7"/>
                    <measurement group_id="O11" value="95.8"/>
                    <measurement group_id="O12" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT; n=17,13,18,15,35,15,35,33,32,24,24,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                    <measurement group_id="O2" value="61.5"/>
                    <measurement group_id="O3" value="77.8"/>
                    <measurement group_id="O4" value="86.7"/>
                    <measurement group_id="O5" value="74.3"/>
                    <measurement group_id="O6" value="66.7"/>
                    <measurement group_id="O7" value="68.6"/>
                    <measurement group_id="O8" value="75.8"/>
                    <measurement group_id="O9" value="96.9"/>
                    <measurement group_id="O10" value="95.8"/>
                    <measurement group_id="O11" value="95.8"/>
                    <measurement group_id="O12" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>All statistical comparisons are for End of Treatment using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The logistic regression model includes the 2 main factors mirabegron dose and solifenacin dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>2.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>3.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>12.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.40</ci_lower_limit>
            <ci_upper_limit>105.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>83.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>79.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>14.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>5.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>35.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>27.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>26.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>5.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Visit in Mean Number of Urgency Incontinence Episodes Per 24 Hours</title>
        <description>Urgency incontinence is the involuntary leakage of urine accompanied by or immediately preceded by urgency, and was derived from the number of incontinence episodes classified by the participant in a 3-day micturition diary as Grade 3 or 4 on the Patient Perception of Intensity of Urgency Scale: 0 = No urgency; 1 = Mild urgency; 2 = Moderate urgency, could postpone voiding a short while; 3 = Severe urgency, could not postpone voiding; 4 = Urge incontinence, leaked before arriving to the toilet.</description>
        <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
        <population>Full Analysis Set-Incontinence participants who had at least 1 urgency (grade 3 or 4) incontinence episode at Baseline, including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;). LOCF was used for the End of Treatment (EOT) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each Visit in Mean Number of Urgency Incontinence Episodes Per 24 Hours</title>
          <description>Urgency incontinence is the involuntary leakage of urine accompanied by or immediately preceded by urgency, and was derived from the number of incontinence episodes classified by the participant in a 3-day micturition diary as Grade 3 or 4 on the Patient Perception of Intensity of Urgency Scale: 0 = No urgency; 1 = Mild urgency; 2 = Moderate urgency, could postpone voiding a short while; 3 = Severe urgency, could not postpone voiding; 4 = Urge incontinence, leaked before arriving to the toilet.</description>
          <population>Full Analysis Set-Incontinence participants who had at least 1 urgency (grade 3 or 4) incontinence episode at Baseline, including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;). LOCF was used for the End of Treatment (EOT) analysis.</population>
          <units>urgency incontinence episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="32"/>
                <count group_id="O10" value="24"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2; n=14,13,17,15,33,12,29,33,31,21,24,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.178"/>
                    <measurement group_id="O2" value="-0.59" spread="0.184"/>
                    <measurement group_id="O3" value="-0.83" spread="0.161"/>
                    <measurement group_id="O4" value="-0.96" spread="0.171"/>
                    <measurement group_id="O5" value="-0.66" spread="0.115"/>
                    <measurement group_id="O6" value="-0.77" spread="0.191"/>
                    <measurement group_id="O7" value="-0.52" spread="0.123"/>
                    <measurement group_id="O8" value="-0.68" spread="0.115"/>
                    <measurement group_id="O9" value="-0.68" spread="0.120"/>
                    <measurement group_id="O10" value="-0.64" spread="0.145"/>
                    <measurement group_id="O11" value="-1.12" spread="0.135"/>
                    <measurement group_id="O12" value="-0.76" spread="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; n=14,10,17,15,34,12,28,30,31,22,24,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.157"/>
                    <measurement group_id="O2" value="-0.48" spread="0.185"/>
                    <measurement group_id="O3" value="-0.93" spread="0.142"/>
                    <measurement group_id="O4" value="-1.13" spread="0.151"/>
                    <measurement group_id="O5" value="-0.77" spread="0.100"/>
                    <measurement group_id="O6" value="-1.00" spread="0.169"/>
                    <measurement group_id="O7" value="-0.73" spread="0.111"/>
                    <measurement group_id="O8" value="-0.70" spread="0.107"/>
                    <measurement group_id="O9" value="-0.81" spread="0.106"/>
                    <measurement group_id="O10" value="-0.86" spread="0.125"/>
                    <measurement group_id="O11" value="-1.20" spread="0.120"/>
                    <measurement group_id="O12" value="-0.68" spread="0.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8; n=14,10,17,14,34,13,29,30,31,21,24,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.173"/>
                    <measurement group_id="O2" value="-0.65" spread="0.204"/>
                    <measurement group_id="O3" value="-1.00" spread="0.157"/>
                    <measurement group_id="O4" value="-1.04" spread="0.172"/>
                    <measurement group_id="O5" value="-0.76" spread="0.110"/>
                    <measurement group_id="O6" value="-1.16" spread="0.179"/>
                    <measurement group_id="O7" value="-0.86" spread="0.119"/>
                    <measurement group_id="O8" value="-0.84" spread=".118"/>
                    <measurement group_id="O9" value="-0.99" spread="0.117"/>
                    <measurement group_id="O10" value="-0.89" spread="0.141"/>
                    <measurement group_id="O11" value="-0.91" spread="0.132"/>
                    <measurement group_id="O12" value="-0.88" spread="0.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12; n=14,10,17,13,34,12,28,30,29,22,24,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.420"/>
                    <measurement group_id="O2" value="-0.54" spread="0.493"/>
                    <measurement group_id="O3" value="-0.87" spread="0.379"/>
                    <measurement group_id="O4" value="-1.13" spread="0.433"/>
                    <measurement group_id="O5" value="-0.83" spread="0.267"/>
                    <measurement group_id="O6" value="-1.13" spread="0.451"/>
                    <measurement group_id="O7" value="-0.81" spread="0.295"/>
                    <measurement group_id="O8" value="-0.91" spread="0.286"/>
                    <measurement group_id="O9" value="-1.19" spread="0.292"/>
                    <measurement group_id="O10" value="-1.06" spread="0.334"/>
                    <measurement group_id="O11" value="-0.28" spread="0.319"/>
                    <measurement group_id="O12" value="-0.93" spread="0.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT; n=14,13,17,15,35,13,29,33,31,23,24,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.411"/>
                    <measurement group_id="O2" value="-0.80" spread="0.424"/>
                    <measurement group_id="O3" value="-0.88" spread="0.372"/>
                    <measurement group_id="O4" value="-1.17" spread="0.394"/>
                    <measurement group_id="O5" value="-0.86" spread="0.258"/>
                    <measurement group_id="O6" value="-1.13" spread="0.424"/>
                    <measurement group_id="O7" value="-0.81" spread="0.283"/>
                    <measurement group_id="O8" value="-0.87" spread="0.266"/>
                    <measurement group_id="O9" value="-1.20" spread="0.277"/>
                    <measurement group_id="O10" value="-1.08" spread="0.321"/>
                    <measurement group_id="O11" value="-0.28" spread="0.312"/>
                    <measurement group_id="O12" value="-0.94" spread="0.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The ANCOVA model including the 2 main factors mirabegron dose and solifenacin dose and their interaction, sex, age group and geographic region as fixed factors and Baseline measurement as a covariate was used to calculate point estimates and 95% confidence intervals for change from Baseline within each treatment group and for differences between combination treatment groups and solifenacin 5 mg as well as for differences between active treatment groups and placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <p_value_desc>All statistical comparisons are for change from Baseline to End of Treatment using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.</p_value_desc>
            <method>Stratified Rank ANCOVA</method>
            <method_desc>P-values are from pairwise comparisons of the combination/active treatment groups vs. solifenacin 5 mg/placebo within a stratified rank ANCOVA model.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.495</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.24</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.383</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.371</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.377</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.08</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.413</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.405</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.435</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.590</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.10</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.552</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.570</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.43</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.487</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.593</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.44</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.500</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.490</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.499</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.32</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.517</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.24</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.516</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Stratified Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.541</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.15</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Visit in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours</title>
        <description>The average number of urgency episodes (the sudden, compelling desire to pass urine, which is difficult to defer), derived from urgency episodes classified by the participant in the 3-day micturition diary as grade 3 or 4 on the Patient Perception of Intensity of Urgency Scale: 0: No urgency; 1: Mild urgency; 2: Moderate urgency, could delay voiding a short while; 3: Severe urgency, could not delay voiding; 4: Urge incontinence, leaked before arriving to the toilet.</description>
        <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
        <population>Full analysis set including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;). LOCF was used for the End of Treatment (EOT) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each Visit in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours</title>
          <description>The average number of urgency episodes (the sudden, compelling desire to pass urine, which is difficult to defer), derived from urgency episodes classified by the participant in the 3-day micturition diary as grade 3 or 4 on the Patient Perception of Intensity of Urgency Scale: 0: No urgency; 1: Mild urgency; 2: Moderate urgency, could delay voiding a short while; 3: Severe urgency, could not delay voiding; 4: Urge incontinence, leaked before arriving to the toilet.</description>
          <population>Full analysis set including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;). LOCF was used for the End of Treatment (EOT) analysis.</population>
          <units>urgency episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2; n=80,71,76,74,148,73,145,145,136,141,77,77</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.07" spread="0.276"/>
                    <measurement group_id="O2" value="-2.06" spread="0.292"/>
                    <measurement group_id="O3" value="-1.91" spread="0.282"/>
                    <measurement group_id="O4" value="-2.49" spread="0.286"/>
                    <measurement group_id="O5" value="-1.63" spread="0.202"/>
                    <measurement group_id="O6" value="-1.97" spread="0.288"/>
                    <measurement group_id="O7" value="-1.84" spread="0.205"/>
                    <measurement group_id="O8" value="-2.59" spread="0.205"/>
                    <measurement group_id="O9" value="-2.30" spread="0.211"/>
                    <measurement group_id="O10" value="-2.57" spread="0.207"/>
                    <measurement group_id="O11" value="-2.35" spread="0.281"/>
                    <measurement group_id="O12" value="-2.23" spread="0.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; n=79,72,74,76,147,73,141,142,138,144,77,75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.55" spread="0.308"/>
                    <measurement group_id="O2" value="-2.70" spread="0.322"/>
                    <measurement group_id="O3" value="-2.70" spread="0.317"/>
                    <measurement group_id="O4" value="-3.16" spread="0.313"/>
                    <measurement group_id="O5" value="-2.24" spread="0.225"/>
                    <measurement group_id="O6" value="-3.02" spread="0.320"/>
                    <measurement group_id="O7" value="-2.64" spread="0.230"/>
                    <measurement group_id="O8" value="-3.14" spread="0.229"/>
                    <measurement group_id="O9" value="-3.08" spread="0.233"/>
                    <measurement group_id="O10" value="-3.17" spread="0.228"/>
                    <measurement group_id="O11" value="-3.04" spread="0.311"/>
                    <measurement group_id="O12" value="-2.81" spread="0.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8; n=77,70,73,75,147,74,143,142,134,145,77,74</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.42" spread="0.318"/>
                    <measurement group_id="O2" value="-2.86" spread="0.332"/>
                    <measurement group_id="O3" value="-3.27" spread="0.325"/>
                    <measurement group_id="O4" value="-3.61" spread="0.321"/>
                    <measurement group_id="O5" value="-2.67" spread="0.229"/>
                    <measurement group_id="O6" value="-3.63" spread="0.323"/>
                    <measurement group_id="O7" value="-3.34" spread="0.232"/>
                    <measurement group_id="O8" value="-3.60" spread="0.233"/>
                    <measurement group_id="O9" value="-3.60" spread="0.240"/>
                    <measurement group_id="O10" value="-3.85" spread="0.231"/>
                    <measurement group_id="O11" value="-3.53" spread="0.317"/>
                    <measurement group_id="O12" value="-3.63" spread="0.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12;n=75,69,73,73,144,73,138,138,133,144,75,73</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.69" spread="0.334"/>
                    <measurement group_id="O2" value="-3.31" spread="0.347"/>
                    <measurement group_id="O3" value="-3.65" spread="0.338"/>
                    <measurement group_id="O4" value="-3.54" spread="0.338"/>
                    <measurement group_id="O5" value="-2.71" spread="0.240"/>
                    <measurement group_id="O6" value="-4.15" spread="0.337"/>
                    <measurement group_id="O7" value="-3.26" spread="0.246"/>
                    <measurement group_id="O8" value="-4.24" spread="0.246"/>
                    <measurement group_id="O9" value="-3.98" spread="0.250"/>
                    <measurement group_id="O10" value="-4.09" spread="0.240"/>
                    <measurement group_id="O11" value="-3.76" spread="0.333"/>
                    <measurement group_id="O12" value="-3.93" spread="0.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT; n=80,76,77,77,150,76,146,147,141,150,78,80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.53" spread="0.328"/>
                    <measurement group_id="O2" value="-3.23" spread="0.336"/>
                    <measurement group_id="O3" value="-3.44" spread="0.334"/>
                    <measurement group_id="O4" value="-3.62" spread="0.334"/>
                    <measurement group_id="O5" value="-2.73" spread="0.239"/>
                    <measurement group_id="O6" value="-3.98" spread="0.336"/>
                    <measurement group_id="O7" value="-3.21" spread="0.242"/>
                    <measurement group_id="O8" value="-3.97" spread="0.242"/>
                    <measurement group_id="O9" value="-3.86" spread="0.247"/>
                    <measurement group_id="O10" value="-4.10" spread="0.239"/>
                    <measurement group_id="O11" value="-3.71" spread="0.332"/>
                    <measurement group_id="O12" value="-3.91" spread="0.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>All statistical comparisons are for change from Baseline to End of Treatment using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The ANCOVA model includes the 2 main factors mirabegron dose and solifenacin dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.
LS Mean Differences were calculated by subtracting Solifenacin 5 mg/Placebo from the comparison treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.412</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.06</ci_lower_limit>
            <ci_upper_limit>-0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.340</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.15</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.340</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.91</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.343</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.80</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.338</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.03</ci_lower_limit>
            <ci_upper_limit>-0.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.409</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.78</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.405</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.98</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.469</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.468</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.468</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.01</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.406</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.469</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.38</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.407</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.408</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.24</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.410</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.14</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.406</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.37</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.467</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.10</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.464</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Visit in Mean Level of Urgency</title>
        <description>Average of participants’ ratings on the degree of urgency associated with each micturition and/or incontinence episode recorded in the 3-day micturition diary according to the Patient Perception of Intensity of Urgency Scale: 0: No urgency; 1: Mild urgency; 2: Moderate urgency, could delay voiding a short while; 3: Severe urgency, could not delay voiding; 4: Urge incontinence, leaked before arriving to the toilet.</description>
        <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
        <population>Full analysis set including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;). LOCF was used for the End of Treatment (EOT) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each Visit in Mean Level of Urgency</title>
          <description>Average of participants’ ratings on the degree of urgency associated with each micturition and/or incontinence episode recorded in the 3-day micturition diary according to the Patient Perception of Intensity of Urgency Scale: 0: No urgency; 1: Mild urgency; 2: Moderate urgency, could delay voiding a short while; 3: Severe urgency, could not delay voiding; 4: Urge incontinence, leaked before arriving to the toilet.</description>
          <population>Full analysis set including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;). LOCF was used for the End of Treatment (EOT) analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2; n=80,71,76,74,148,73,145,145,136,141,77,77</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.043"/>
                    <measurement group_id="O2" value="-0.19" spread="0.046"/>
                    <measurement group_id="O3" value="-0.15" spread="0.044"/>
                    <measurement group_id="O4" value="-0.25" spread="0.045"/>
                    <measurement group_id="O5" value="-0.14" spread="0.032"/>
                    <measurement group_id="O6" value="-0.21" spread="0.045"/>
                    <measurement group_id="O7" value="-0.19" spread="0.032"/>
                    <measurement group_id="O8" value="-0.26" spread="0.032"/>
                    <measurement group_id="O9" value="-0.26" spread="0.033"/>
                    <measurement group_id="O10" value="-0.28" spread="0.033"/>
                    <measurement group_id="O11" value="-0.31" spread="0.044"/>
                    <measurement group_id="O12" value="-0.20" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; n=79,72,74,76,147,73,141,142,138,144,77,75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.052"/>
                    <measurement group_id="O2" value="-0.28" spread="0.054"/>
                    <measurement group_id="O3" value="-0.26" spread="0.053"/>
                    <measurement group_id="O4" value="-0.33" spread="0.053"/>
                    <measurement group_id="O5" value="-0.23" spread="0.038"/>
                    <measurement group_id="O6" value="-0.35" spread="0.054"/>
                    <measurement group_id="O7" value="-0.32" spread="0.039"/>
                    <measurement group_id="O8" value="-0.35" spread="0.039"/>
                    <measurement group_id="O9" value="-0.35" spread="0.039"/>
                    <measurement group_id="O10" value="-0.37" spread="0.038"/>
                    <measurement group_id="O11" value="-0.41" spread="0.052"/>
                    <measurement group_id="O12" value="-0.31" spread="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8; n=77,70,73,75,147,74,143,142,134,145,77,74</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.059"/>
                    <measurement group_id="O2" value="-0.30" spread="0.062"/>
                    <measurement group_id="O3" value="-0.36" spread="0.061"/>
                    <measurement group_id="O4" value="-0.45" spread="0.060"/>
                    <measurement group_id="O5" value="-0.30" spread="0.043"/>
                    <measurement group_id="O6" value="-0.44" spread="0.60"/>
                    <measurement group_id="O7" value="-0.39" spread="0.043"/>
                    <measurement group_id="O8" value="-0.41" spread="0.044"/>
                    <measurement group_id="O9" value="-0.45" spread="0.045"/>
                    <measurement group_id="O10" value="-0.46" spread="0.043"/>
                    <measurement group_id="O11" value="-0.53" spread="0.059"/>
                    <measurement group_id="O12" value="-0.43" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12;n=75,69,73,73,144,73,138,138,133,144,75,73</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.064"/>
                    <measurement group_id="O2" value="-0.35" spread="0.067"/>
                    <measurement group_id="O3" value="-0.44" spread="0.065"/>
                    <measurement group_id="O4" value="-0.42" spread="0.065"/>
                    <measurement group_id="O5" value="-0.33" spread="0.046"/>
                    <measurement group_id="O6" value="-0.49" spread="0.065"/>
                    <measurement group_id="O7" value="-0.43" spread="0.047"/>
                    <measurement group_id="O8" value="-0.54" spread="0.047"/>
                    <measurement group_id="O9" value="-0.50" spread="0.048"/>
                    <measurement group_id="O10" value="-0.54" spread="0.046"/>
                    <measurement group_id="O11" value="-0.61" spread="0.064"/>
                    <measurement group_id="O12" value="-0.49" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT; n=80,76,77,77,150,76,146,147,141,150,78,80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.063"/>
                    <measurement group_id="O2" value="-0.33" spread="0.064"/>
                    <measurement group_id="O3" value="-0.41" spread="0.064"/>
                    <measurement group_id="O4" value="-0.45" spread="0.064"/>
                    <measurement group_id="O5" value="-0.33" spread="0.064"/>
                    <measurement group_id="O6" value="-0.47" spread="0.064"/>
                    <measurement group_id="O7" value="-0.42" spread="0.046"/>
                    <measurement group_id="O8" value="-0.50" spread="0.046"/>
                    <measurement group_id="O9" value="-0.48" spread="0.047"/>
                    <measurement group_id="O10" value="-0.55" spread="0.046"/>
                    <measurement group_id="O11" value="-0.59" spread="0.063"/>
                    <measurement group_id="O12" value="-0.47" spread="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>All statistical comparisons are for change from Baseline to End of Treatment using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The ANCOVA model includes the 2 main factors mirabegron dose and solifenacin dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.
LS Mean Differences were calculated by subtracting Solifenacin 5 mg/Placebo from the comparison treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.079</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.065</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.065</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.066</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.065</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.078</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.077</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.090</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.089</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.089</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.086</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.077</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.090</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.078</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.078</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.078</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.077</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.089</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.088</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Visit in Mean Number of Pads Used Per 24 Hours</title>
        <description>The average number of times a participant recorded a new pad used per day during the 3-day micturition diary period.</description>
        <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
        <population>Full analysis set participants who had at least one use of pad at baseline, and including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;). LOCF was used for the End of Treatment (EOT) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each Visit in Mean Number of Pads Used Per 24 Hours</title>
          <description>The average number of times a participant recorded a new pad used per day during the 3-day micturition diary period.</description>
          <population>Full analysis set participants who had at least one use of pad at baseline, and including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;). LOCF was used for the End of Treatment (EOT) analysis.</population>
          <units>pads</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2; n=33,33,34,31,74,23,62,55,62,62,45,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.212"/>
                    <measurement group_id="O2" value="-0.87" spread="0.212"/>
                    <measurement group_id="O3" value="-0.88" spread="0.209"/>
                    <measurement group_id="O4" value="-1.31" spread="0.219"/>
                    <measurement group_id="O5" value="-0.92" spread="0.142"/>
                    <measurement group_id="O6" value="-0.91" spread="0.255"/>
                    <measurement group_id="O7" value="-0.86" spread="0.155"/>
                    <measurement group_id="O8" value="-0.96" spread="0.164"/>
                    <measurement group_id="O9" value="-0.89" spread="0.155"/>
                    <measurement group_id="O10" value="-1.02" spread="0.155"/>
                    <measurement group_id="O11" value="-1.13" spread="0.182"/>
                    <measurement group_id="O12" value="-1.31" spread="0.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; n=32,31,35,31,75,23,61,52,64,62,45,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.224"/>
                    <measurement group_id="O2" value="-0.93" spread="0.228"/>
                    <measurement group_id="O3" value="-0.70" spread="0.214"/>
                    <measurement group_id="O4" value="-1.62" spread="0.228"/>
                    <measurement group_id="O5" value="-1.26" spread="0.147"/>
                    <measurement group_id="O6" value="-1.23" spread="0.265"/>
                    <measurement group_id="O7" value="-0.94" spread="0.162"/>
                    <measurement group_id="O8" value="-1.09" spread="0.176"/>
                    <measurement group_id="O9" value="-1.24" spread="0.159"/>
                    <measurement group_id="O10" value="-1.30" spread="0.161"/>
                    <measurement group_id="O11" value="-1.35" spread="0.189"/>
                    <measurement group_id="O12" value="-1.36" spread="0.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8; n=30,31,34,31,74,24,63,52,64,61,45,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="0.226"/>
                    <measurement group_id="O2" value="-0.90" spread="0.223"/>
                    <measurement group_id="O3" value="-1.11" spread="0.213"/>
                    <measurement group_id="O4" value="-1.47" spread="0.223"/>
                    <measurement group_id="O5" value="-1.25" spread="0.144"/>
                    <measurement group_id="O6" value="-1.53" spread="0.253"/>
                    <measurement group_id="O7" value="-1.10" spread="0.156"/>
                    <measurement group_id="O8" value="-1.39" spread="0.172"/>
                    <measurement group_id="O9" value="-1.29" spread="0.155"/>
                    <measurement group_id="O10" value="-1.51" spread="0.159"/>
                    <measurement group_id="O11" value="-1.37" spread="0.185"/>
                    <measurement group_id="O12" value="-1.56" spread="0.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12; n=30,31,34,29,72,23,60,52,63,62,45,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="0.246"/>
                    <measurement group_id="O2" value="-0.97" spread="0.242"/>
                    <measurement group_id="O3" value="-0.93" spread="0.231"/>
                    <measurement group_id="O4" value="-1.35" spread="0.251"/>
                    <measurement group_id="O5" value="-1.39" spread="0.159"/>
                    <measurement group_id="O6" value="-1.75" spread="0.282"/>
                    <measurement group_id="O7" value="-1.02" spread="0.174"/>
                    <measurement group_id="O8" value="-1.44" spread="0.187"/>
                    <measurement group_id="O9" value="-1.45" spread="0.170"/>
                    <measurement group_id="O10" value="-1.63" spread="0.172"/>
                    <measurement group_id="O11" value="-1.60" spread="0.201"/>
                    <measurement group_id="O12" value="-1.60" spread="0.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT; n=33,34,35,32,76,24,63,56,64,65,46,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.244"/>
                    <measurement group_id="O2" value="-1.04" spread="0.241"/>
                    <measurement group_id="O3" value="-0.95" spread="0.237"/>
                    <measurement group_id="O4" value="-1.44" spread="0.248"/>
                    <measurement group_id="O5" value="-1.38" spread="0.161"/>
                    <measurement group_id="O6" value="-1.73" spread="0.287"/>
                    <measurement group_id="O7" value="-1.04" spread="0.177"/>
                    <measurement group_id="O8" value="-1.38" spread="0.188"/>
                    <measurement group_id="O9" value="-1.46" spread="0.176"/>
                    <measurement group_id="O10" value="-1.63" spread="0.174"/>
                    <measurement group_id="O11" value="-1.59" spread="0.207"/>
                    <measurement group_id="O12" value="-1.63" spread="0.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>All statistical comparisons are for change from Baseline to End of Treatment using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The ANCOVA model includes the 2 main factors mirabegron dose and solifenacin dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.
LS Mean Differences were calculated by subtracting Solifenacin 5 mg/Placebo from the comparison treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.330</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.239</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.248</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.239</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.238</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.262</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.296</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.343</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.08</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.340</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.98</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.348</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.293</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.33</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.377</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.84</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.301</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.308</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.35</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.301</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.41</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.300</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.59</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.320</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.59</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.348</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.68</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Visit in Mean Number of Nocturia Episodes Per 24-Hours</title>
        <description>Nocturia is defined as waking at night one or more times to void. The average number of times a participant urinated (excluding incontinence only episodes) during sleeping time per day was derived from the 3-day micturition diary.</description>
        <time_frame>Baseline and Weeks 2, 4, 8 and 12</time_frame>
        <population>Full analysis set participants who had at least one nocturia episode at baseline, and including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;). LOCF was used for the End of Treatment (EOT) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each Visit in Mean Number of Nocturia Episodes Per 24-Hours</title>
          <description>Nocturia is defined as waking at night one or more times to void. The average number of times a participant urinated (excluding incontinence only episodes) during sleeping time per day was derived from the 3-day micturition diary.</description>
          <population>Full analysis set participants who had at least one nocturia episode at baseline, and including participants with available data at Baseline and each post-baseline visit (indicated by &quot;n&quot;). LOCF was used for the End of Treatment (EOT) analysis.</population>
          <units>nocturia episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2; n=78,69,75,72,144,71,142,138,133,138,74,73</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.115"/>
                    <measurement group_id="O2" value="-0.37" spread="0.123"/>
                    <measurement group_id="O3" value="-0.60" spread="0.118"/>
                    <measurement group_id="O4" value="-0.38" spread="0.120"/>
                    <measurement group_id="O5" value="-0.30" spread="0.085"/>
                    <measurement group_id="O6" value="-0.45" spread="0.121"/>
                    <measurement group_id="O7" value="-0.43" spread="0.086"/>
                    <measurement group_id="O8" value="-0.51" spread="0.087"/>
                    <measurement group_id="O9" value="-0.49" spread="0.088"/>
                    <measurement group_id="O10" value="-0.61" spread="0.087"/>
                    <measurement group_id="O11" value="-0.43" spread="0.119"/>
                    <measurement group_id="O12" value="-0.53" spread="0.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; n=77,69,74,74,143,71,138,135,134,141,74,71</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.116"/>
                    <measurement group_id="O2" value="-0.60" spread="0.123"/>
                    <measurement group_id="O3" value="-0.71" spread="0.118"/>
                    <measurement group_id="O4" value="-0.55" spread="0.118"/>
                    <measurement group_id="O5" value="-0.47" spread="0.085"/>
                    <measurement group_id="O6" value="-0.74" spread="0.121"/>
                    <measurement group_id="O7" value="-0.59" spread="0.087"/>
                    <measurement group_id="O8" value="-0.54" spread="0.088"/>
                    <measurement group_id="O9" value="-0.69" spread="0.088"/>
                    <measurement group_id="O10" value="-0.80" spread="0.086"/>
                    <measurement group_id="O11" value="-0.67" spread="0.119"/>
                    <measurement group_id="O12" value="-0.75" spread="0.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8; n=75,67,73,73,143,72,140,135,130,142,74,70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.126"/>
                    <measurement group_id="O2" value="-0.65" spread="0.133"/>
                    <measurement group_id="O3" value="-0.68" spread="0.127"/>
                    <measurement group_id="O4" value="-0.80" spread="0.127"/>
                    <measurement group_id="O5" value="-0.65" spread="0.091"/>
                    <measurement group_id="O6" value="-1.01" spread="0.128"/>
                    <measurement group_id="O7" value="-0.76" spread="0.092"/>
                    <measurement group_id="O8" value="-0.79" spread="0.094"/>
                    <measurement group_id="O9" value="-0.76" spread="0.095"/>
                    <measurement group_id="O10" value="-0.98" spread="0.091"/>
                    <measurement group_id="O11" value="-0.81" spread="0.127"/>
                    <measurement group_id="O12" value="-0.91" spread="0.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12;n=73,66,73,71,140,71,135,131,130,141,72,69</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.146"/>
                    <measurement group_id="O2" value="-0.69" spread="0.154"/>
                    <measurement group_id="O3" value="-0.84" spread="0.146"/>
                    <measurement group_id="O4" value="-0.59" spread="0.148"/>
                    <measurement group_id="O5" value="-0.70" spread="0.106"/>
                    <measurement group_id="O6" value="-0.99" spread="0.148"/>
                    <measurement group_id="O7" value="-0.75" spread="0.108"/>
                    <measurement group_id="O8" value="-0.81" spread="0.109"/>
                    <measurement group_id="O9" value="-0.80" spread="0.110"/>
                    <measurement group_id="O10" value="-1.05" spread="0.105"/>
                    <measurement group_id="O11" value="-0.98" spread="0.147"/>
                    <measurement group_id="O12" value="-1.03" spread="0.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT; n=78,73,76,75,146,74,143,140,137,147,75,76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.140"/>
                    <measurement group_id="O2" value="-0.69" spread="0.145"/>
                    <measurement group_id="O3" value="-0.82" spread="0.142"/>
                    <measurement group_id="O4" value="-0.68" spread="0.143"/>
                    <measurement group_id="O5" value="-0.69" spread="0.102"/>
                    <measurement group_id="O6" value="-0.95" spread="0.144"/>
                    <measurement group_id="O7" value="-0.73" spread="0.104"/>
                    <measurement group_id="O8" value="-0.77" spread="0.105"/>
                    <measurement group_id="O9" value="-0.77" spread="0.106"/>
                    <measurement group_id="O10" value="-1.04" spread="0.102"/>
                    <measurement group_id="O11" value="-0.94" spread="0.143"/>
                    <measurement group_id="O12" value="-0.96" spread="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>All statistical comparisons are for change from Baseline to End of Treatment using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The ANCOVA model includes the 2 main factors mirabegron dose and solifenacin dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.
LS Mean Differences were calculated by subtracting Solifenacin 5 mg/Placebo from the comparison treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.177</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.146</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.146</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.147</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.145</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.176</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.175</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.81</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.201</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.199</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.200</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.81</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.201</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.174</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.175</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.175</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.080</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.173</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.200</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.199</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Treatment in Patient Perception of Bladder Condition (PPBC)</title>
        <description>The PPBC scale is a global assessment tool that asks patients to rate their impression of their current bladder condition on a 6-point scale from 1: 'Does not cause me any problems at all'; 2: 'Causes me some very minor problems'; 3: 'Causes me some minor problems’; 4: 'Causes me (some) moderate problems'; 5: 'Causes me severe problems' and 6: 'Causes me many severe problems'. A negative change from Baseline score indicates improvement.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment in Patient Perception of Bladder Condition (PPBC)</title>
          <description>The PPBC scale is a global assessment tool that asks patients to rate their impression of their current bladder condition on a 6-point scale from 1: 'Does not cause me any problems at all'; 2: 'Causes me some very minor problems'; 3: 'Causes me some minor problems’; 4: 'Causes me (some) moderate problems'; 5: 'Causes me severe problems' and 6: 'Causes me many severe problems'. A negative change from Baseline score indicates improvement.</description>
          <population>Full Analysis Set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="147"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="141"/>
                <count group_id="O8" value="143"/>
                <count group_id="O9" value="136"/>
                <count group_id="O10" value="144"/>
                <count group_id="O11" value="76"/>
                <count group_id="O12" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.14"/>
                    <measurement group_id="O2" value="-1.4" spread="0.14"/>
                    <measurement group_id="O3" value="-1.5" spread="0.14"/>
                    <measurement group_id="O4" value="-1.5" spread="0.14"/>
                    <measurement group_id="O5" value="-1.3" spread="0.10"/>
                    <measurement group_id="O6" value="-1.5" spread="0.14"/>
                    <measurement group_id="O7" value="-1.4" spread="0.10"/>
                    <measurement group_id="O8" value="-1.7" spread="0.10"/>
                    <measurement group_id="O9" value="-1.7" spread="0.10"/>
                    <measurement group_id="O10" value="-1.8" spread="0.10"/>
                    <measurement group_id="O11" value="-1.8" spread="0.14"/>
                    <measurement group_id="O12" value="-1.6" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Statistical comparisons were made using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The ANCOVA model for all pairwise comparisons includes the 2 main factors mirabegron dose and solifenacin succinate dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.
LS Mean Differences were calculated by subtracting Solifenacin 5 mg/Placebo from the comparison treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Improvement in PPBC</title>
        <description>The PPBC scale is a global assessment tool that asks patients to rate their impression of their current bladder condition on a 6-point scale from 1: 'Does not cause me any problems at all'; 2: 'Causes me some very minor problems'; 3: 'Causes me some minor problems'; 4: 'Causes me (some) moderate problems'; 5: 'Causes me severe problems' and 6: 'Causes me many severe problems'. Improvement was defined as at least a 1-point improvement (decrease) from Baseline in PPBC score.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement in PPBC</title>
          <description>The PPBC scale is a global assessment tool that asks patients to rate their impression of their current bladder condition on a 6-point scale from 1: 'Does not cause me any problems at all'; 2: 'Causes me some very minor problems'; 3: 'Causes me some minor problems'; 4: 'Causes me (some) moderate problems'; 5: 'Causes me severe problems' and 6: 'Causes me many severe problems'. Improvement was defined as at least a 1-point improvement (decrease) from Baseline in PPBC score.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="147"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="141"/>
                <count group_id="O8" value="143"/>
                <count group_id="O9" value="136"/>
                <count group_id="O10" value="144"/>
                <count group_id="O11" value="76"/>
                <count group_id="O12" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="76.7"/>
                    <measurement group_id="O3" value="78.9"/>
                    <measurement group_id="O4" value="68.0"/>
                    <measurement group_id="O5" value="72.8"/>
                    <measurement group_id="O6" value="84.9"/>
                    <measurement group_id="O7" value="74.5"/>
                    <measurement group_id="O8" value="83.2"/>
                    <measurement group_id="O9" value="77.9"/>
                    <measurement group_id="O10" value="82.6"/>
                    <measurement group_id="O11" value="82.9"/>
                    <measurement group_id="O12" value="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>All statistical comparisons are for End of Treatment using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The logistic regression model includes the 2 main factors mirabegron dose and solifenacin dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.040</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>4.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>3.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>3.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>3.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>2.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>2.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>3.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>5.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>2.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>3.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>2.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>4.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>3.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Major Improvement in PPBC</title>
        <description>The PPBC scale is a global assessment tool that asks patients to rate their impression of their current bladder condition on a 6-point scale from 1: 'Does not cause me any problems at all'; 2: 'Causes me some very minor problems'; 3: 'Causes me some minor problems'; 4: 'Causes me (some) moderate problems'; 5: 'Causes me severe problems' and 6: 'Causes me many severe problems'. Major improvement was defined as at least a 2-point improvement (decrease) from Baseline in PPBC score.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Major Improvement in PPBC</title>
          <description>The PPBC scale is a global assessment tool that asks patients to rate their impression of their current bladder condition on a 6-point scale from 1: 'Does not cause me any problems at all'; 2: 'Causes me some very minor problems'; 3: 'Causes me some minor problems'; 4: 'Causes me (some) moderate problems'; 5: 'Causes me severe problems' and 6: 'Causes me many severe problems'. Major improvement was defined as at least a 2-point improvement (decrease) from Baseline in PPBC score.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="147"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="141"/>
                <count group_id="O8" value="143"/>
                <count group_id="O9" value="136"/>
                <count group_id="O10" value="144"/>
                <count group_id="O11" value="76"/>
                <count group_id="O12" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7"/>
                    <measurement group_id="O2" value="42.5"/>
                    <measurement group_id="O3" value="38.2"/>
                    <measurement group_id="O4" value="44.0"/>
                    <measurement group_id="O5" value="42.2"/>
                    <measurement group_id="O6" value="46.6"/>
                    <measurement group_id="O7" value="48.2"/>
                    <measurement group_id="O8" value="52.4"/>
                    <measurement group_id="O9" value="54.4"/>
                    <measurement group_id="O10" value="54.9"/>
                    <measurement group_id="O11" value="57.9"/>
                    <measurement group_id="O12" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>2.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>2.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.072</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>3.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>2.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>2.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>2.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>3.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>3.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>3.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>2.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Deterioration in PPBC</title>
        <description>The PPBC scale is a global assessment tool that asks patients to rate their impression of their current bladder condition on a 6-point scale from 1: 'Does not cause me any problems at all'; 2: 'Causes me some very minor problems'; 3: 'Causes me some minor problems'; 4: 'Causes me (some) moderate problems'; 5: 'Causes me severe problems' and 6: 'Causes me many severe problems'. Deterioration was defined as at least a 1 point increase from Baseline in PPBC score.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Deterioration in PPBC</title>
          <description>The PPBC scale is a global assessment tool that asks patients to rate their impression of their current bladder condition on a 6-point scale from 1: 'Does not cause me any problems at all'; 2: 'Causes me some very minor problems'; 3: 'Causes me some minor problems'; 4: 'Causes me (some) moderate problems'; 5: 'Causes me severe problems' and 6: 'Causes me many severe problems'. Deterioration was defined as at least a 1 point increase from Baseline in PPBC score.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="147"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="141"/>
                <count group_id="O8" value="143"/>
                <count group_id="O9" value="136"/>
                <count group_id="O10" value="144"/>
                <count group_id="O11" value="76"/>
                <count group_id="O12" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4"/>
                    <measurement group_id="O2" value="4.1"/>
                    <measurement group_id="O3" value="5.3"/>
                    <measurement group_id="O4" value="4.0"/>
                    <measurement group_id="O5" value="4.8"/>
                    <measurement group_id="O6" value="2.7"/>
                    <measurement group_id="O7" value="4.3"/>
                    <measurement group_id="O8" value="2.8"/>
                    <measurement group_id="O9" value="2.9"/>
                    <measurement group_id="O10" value="1.4"/>
                    <measurement group_id="O11" value="1.3"/>
                    <measurement group_id="O12" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>All statistical comparisons are for End of Treatment using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The logistic regression model includes the 2 main factors mirabegron dose and solifenacin dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>2.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>2.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>3.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>5.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>5.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>4.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>3.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>3.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>2.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>3.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>3.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>6.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Treatment in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)</title>
        <description>Overactive bladder symptoms were assessed using the symptom bother scale of the overactive bladder questionnaire. The symptom bother scale consists of 8 questions answered by the participant on a scale from 1-6. The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 to 100, with 100 indicating worst severity. A negative change from Baseline in symptom bother score indicates improvements.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)</title>
          <description>Overactive bladder symptoms were assessed using the symptom bother scale of the overactive bladder questionnaire. The symptom bother scale consists of 8 questions answered by the participant on a scale from 1-6. The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 to 100, with 100 indicating worst severity. A negative change from Baseline in symptom bother score indicates improvements.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="75"/>
                <count group_id="O7" value="144"/>
                <count group_id="O8" value="145"/>
                <count group_id="O9" value="139"/>
                <count group_id="O10" value="146"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.5" spread="1.96"/>
                    <measurement group_id="O2" value="-27.1" spread="2.01"/>
                    <measurement group_id="O3" value="-27.5" spread="2.00"/>
                    <measurement group_id="O4" value="-29.8" spread="1.99"/>
                    <measurement group_id="O5" value="-26.8" spread="1.42"/>
                    <measurement group_id="O6" value="-29.9" spread="2.01"/>
                    <measurement group_id="O7" value="-28.0" spread="1.45"/>
                    <measurement group_id="O8" value="-31.7" spread="1.45"/>
                    <measurement group_id="O9" value="-32.0" spread="1.48"/>
                    <measurement group_id="O10" value="-33.5" spread="1.44"/>
                    <measurement group_id="O11" value="-33.6" spread="1.97"/>
                    <measurement group_id="O12" value="-31.4" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Statistical comparisons were made using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The ANCOVA model for all pairwise comparisons includes the 2 main factors mirabegron dose and solifenacin succinate dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.
LS Mean Differences were calculated by subtracting Solifenacin 5 mg/Placebo from the comparison treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.9</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-5.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.7</ci_lower_limit>
            <ci_upper_limit>-2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.6</ci_lower_limit>
            <ci_upper_limit>-2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.5</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.8</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.9</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.9</ci_lower_limit>
            <ci_upper_limit>-1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.3</ci_lower_limit>
            <ci_upper_limit>-1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-8.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.8</ci_lower_limit>
            <ci_upper_limit>-3.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-8.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.5</ci_lower_limit>
            <ci_upper_limit>-2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-5.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.4</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Symptom Bother Response</title>
        <description>Overactive bladder symptoms were assessed using the symptom bother scale of the overactive bladder questionnaire. The symptom bother scale consists of 8 questions answered by the participant on a scale from 1-6. The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 to 100, with 100 indicating worst severity. Symptom bother response is defined as improvement (decrease) of at least 10 points from Baseline.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Symptom Bother Response</title>
          <description>Overactive bladder symptoms were assessed using the symptom bother scale of the overactive bladder questionnaire. The symptom bother scale consists of 8 questions answered by the participant on a scale from 1-6. The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 to 100, with 100 indicating worst severity. Symptom bother response is defined as improvement (decrease) of at least 10 points from Baseline.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="75"/>
                <count group_id="O7" value="144"/>
                <count group_id="O8" value="145"/>
                <count group_id="O9" value="139"/>
                <count group_id="O10" value="146"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4"/>
                    <measurement group_id="O2" value="84.0"/>
                    <measurement group_id="O3" value="78.9"/>
                    <measurement group_id="O4" value="85.7"/>
                    <measurement group_id="O5" value="81.3"/>
                    <measurement group_id="O6" value="85.3"/>
                    <measurement group_id="O7" value="82.6"/>
                    <measurement group_id="O8" value="85.5"/>
                    <measurement group_id="O9" value="85.6"/>
                    <measurement group_id="O10" value="88.4"/>
                    <measurement group_id="O11" value="88.5"/>
                    <measurement group_id="O12" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>All statistical comparisons are for End of Treatment using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The logistic regression model includes the 2 main factors mirabegron dose and solifenacin dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>3.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>2.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>2.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>3.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>3.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.81</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>4.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>2.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>4.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>3.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>5.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>3.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>3.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>4.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.22</ci_lower_limit>
            <ci_upper_limit>5.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>5.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>3.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Treatment in Health-related Quality of Life (HRQL) Total Score</title>
        <description>Health-related quality of life was assessed by the HRQL subscales (coping, concern, sleep and social interaction) of the overactive bladder questionnaire (OABq). The HRQL total score was calculated by adding the 4 HRQL subscale scores, and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from Baseline in HRQL score indicates improvements.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment in Health-related Quality of Life (HRQL) Total Score</title>
          <description>Health-related quality of life was assessed by the HRQL subscales (coping, concern, sleep and social interaction) of the overactive bladder questionnaire (OABq). The HRQL total score was calculated by adding the 4 HRQL subscale scores, and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from Baseline in HRQL score indicates improvements.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="75"/>
                <count group_id="O7" value="144"/>
                <count group_id="O8" value="145"/>
                <count group_id="O9" value="139"/>
                <count group_id="O10" value="146"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="2.03"/>
                    <measurement group_id="O2" value="22.5" spread="2.08"/>
                    <measurement group_id="O3" value="25.8" spread="2.07"/>
                    <measurement group_id="O4" value="27.7" spread="2.05"/>
                    <measurement group_id="O5" value="23.7" spread="1.47"/>
                    <measurement group_id="O6" value="26.6" spread="2.08"/>
                    <measurement group_id="O7" value="25.5" spread="1.50"/>
                    <measurement group_id="O8" value="28.5" spread="1.50"/>
                    <measurement group_id="O9" value="29.2" spread="1.53"/>
                    <measurement group_id="O10" value="30.1" spread="1.49"/>
                    <measurement group_id="O11" value="30.3" spread="2.04"/>
                    <measurement group_id="O12" value="28.9" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Statistical comparisons were made using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The ANCOVA model for all pairwise comparisons includes the 2 main factors mirabegron dose and solifenacin succinate dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.
LS Mean Differences were calculated by subtracting Solifenacin 5 mg/Placebo from the comparison treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>7.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Differrence</param_type>
            <param_value>4.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>8.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>9.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>6.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.3</ci_lower_limit>
            <ci_upper_limit>10.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>6.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.7</ci_lower_limit>
            <ci_upper_limit>11.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>10.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.7</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>7.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>8.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>7.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>9.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>9.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>11.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Health-related Quality of Life Total Score Response</title>
        <description>Health-related quality of life was assessed by the HRQL subscales (coping, concern, sleep and social interaction) of the overactive bladder questionnaire (OABq). The HRQL total score was calculated by adding the 4 HRQL subscale scores, and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. HRQL response is defined as improvement (decrease) of at least 10 points from Baseline.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Health-related Quality of Life Total Score Response</title>
          <description>Health-related quality of life was assessed by the HRQL subscales (coping, concern, sleep and social interaction) of the overactive bladder questionnaire (OABq). The HRQL total score was calculated by adding the 4 HRQL subscale scores, and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. HRQL response is defined as improvement (decrease) of at least 10 points from Baseline.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="75"/>
                <count group_id="O7" value="144"/>
                <count group_id="O8" value="145"/>
                <count group_id="O9" value="139"/>
                <count group_id="O10" value="146"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1"/>
                    <measurement group_id="O2" value="57.3"/>
                    <measurement group_id="O3" value="71.1"/>
                    <measurement group_id="O4" value="74.0"/>
                    <measurement group_id="O5" value="72.7"/>
                    <measurement group_id="O6" value="74.7"/>
                    <measurement group_id="O7" value="72.9"/>
                    <measurement group_id="O8" value="78.6"/>
                    <measurement group_id="O9" value="77.0"/>
                    <measurement group_id="O10" value="84.2"/>
                    <measurement group_id="O11" value="79.5"/>
                    <measurement group_id="O12" value="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>All statistical comparisons were made using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The logistic regression model includes the 2 main factors mirabegron dose and solifenacin dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>2.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>4.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>2.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>3.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>2.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>2.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>3.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.22</ci_lower_limit>
            <ci_upper_limit>4.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>3.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>3.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Mobility Score</title>
        <description>The EQ-5D is an international, standardized, nondisease-specific (i.e., generic) instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their health state:
I have no problems in walking about; I have some problems in walking about; I am confined to bed.
In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of patients in that category.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Mobility Score</title>
          <description>The EQ-5D is an international, standardized, nondisease-specific (i.e., generic) instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their health state:
I have no problems in walking about; I have some problems in walking about; I am confined to bed.
In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of patients in that category.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No problem → No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="59"/>
                    <measurement group_id="O5" value="118"/>
                    <measurement group_id="O6" value="54"/>
                    <measurement group_id="O7" value="94"/>
                    <measurement group_id="O8" value="113"/>
                    <measurement group_id="O9" value="102"/>
                    <measurement group_id="O10" value="120"/>
                    <measurement group_id="O11" value="59"/>
                    <measurement group_id="O12" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problem → Some problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problem → Confined to bed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problem → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some problems → No problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="14"/>
                    <measurement group_id="O11" value="11"/>
                    <measurement group_id="O12" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some problems → Some problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="12"/>
                    <measurement group_id="O9" value="15"/>
                    <measurement group_id="O10" value="11"/>
                    <measurement group_id="O11" value="8"/>
                    <measurement group_id="O12" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some problems → Confined to bed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some problems → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confined → No problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confined → Some problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confined → Confined to bed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confined → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Some problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Confined to bed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Self-care Score</title>
        <description>The EQ-5D is an international, standardized, nondisease-specific (i.e., generic) instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their health state:
I have no problems with self-care; I have some problems washing or dressing myself; I am unable to wash or dress myself.
In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of patients in that category.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Self-care Score</title>
          <description>The EQ-5D is an international, standardized, nondisease-specific (i.e., generic) instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their health state:
I have no problems with self-care; I have some problems washing or dressing myself; I am unable to wash or dress myself.
In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of patients in that category.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No problem → No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="72"/>
                    <measurement group_id="O5" value="138"/>
                    <measurement group_id="O6" value="68"/>
                    <measurement group_id="O7" value="128"/>
                    <measurement group_id="O8" value="138"/>
                    <measurement group_id="O9" value="130"/>
                    <measurement group_id="O10" value="141"/>
                    <measurement group_id="O11" value="74"/>
                    <measurement group_id="O12" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problem → Some problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problem → Unable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problem → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some problems → No problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some problems → Some problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some problems → Unable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some problems → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable → No problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable → Some problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable → Unable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Some problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Unable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score</title>
        <description>The EQ-5D is a standardized, nondisease-specific instrument for describing health status. Participants were asked which statement best describes their health state with regard to usual activities (work, study or leisure): I have no problems performing my usual activities; I have some problems performing my usual activities; I am unable to perform my usual activities.
In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of patients in that category.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score</title>
          <description>The EQ-5D is a standardized, nondisease-specific instrument for describing health status. Participants were asked which statement best describes their health state with regard to usual activities (work, study or leisure): I have no problems performing my usual activities; I have some problems performing my usual activities; I am unable to perform my usual activities.
In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of patients in that category.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No problem → No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="60"/>
                    <measurement group_id="O5" value="115"/>
                    <measurement group_id="O6" value="57"/>
                    <measurement group_id="O7" value="89"/>
                    <measurement group_id="O8" value="110"/>
                    <measurement group_id="O9" value="106"/>
                    <measurement group_id="O10" value="109"/>
                    <measurement group_id="O11" value="57"/>
                    <measurement group_id="O12" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problem → Some problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problem → Unable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problem → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some problems → No problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="29"/>
                    <measurement group_id="O8" value="24"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="21"/>
                    <measurement group_id="O11" value="14"/>
                    <measurement group_id="O12" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some problems → Some problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="12"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some problems → Unable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some problems → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable → No problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable → Some problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable → Unable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Some problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Unable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score</title>
        <description>The EQ-5D is an international, standardized, nondisease-specific (i.e., generic) instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their health state:
I have no pain or discomfort; I have moderate pain or discomfort; I have extreme pain or discomfort. In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of participants in that category.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score</title>
          <description>The EQ-5D is an international, standardized, nondisease-specific (i.e., generic) instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their health state:
I have no pain or discomfort; I have moderate pain or discomfort; I have extreme pain or discomfort. In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of participants in that category.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No pain → No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="70"/>
                    <measurement group_id="O6" value="35"/>
                    <measurement group_id="O7" value="67"/>
                    <measurement group_id="O8" value="61"/>
                    <measurement group_id="O9" value="66"/>
                    <measurement group_id="O10" value="73"/>
                    <measurement group_id="O11" value="39"/>
                    <measurement group_id="O12" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No pain → Moderate pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="14"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="8"/>
                    <measurement group_id="O12" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No pain → Extreme pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No pain → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain → No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="34"/>
                    <measurement group_id="O9" value="28"/>
                    <measurement group_id="O10" value="36"/>
                    <measurement group_id="O11" value="14"/>
                    <measurement group_id="O12" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain → Moderate pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="37"/>
                    <measurement group_id="O8" value="33"/>
                    <measurement group_id="O9" value="27"/>
                    <measurement group_id="O10" value="25"/>
                    <measurement group_id="O11" value="12"/>
                    <measurement group_id="O12" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain → Extreme pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme pain → No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme pain → Moderate pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme pain → Extreme pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme pain → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Moderate pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Extreme pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score</title>
        <description>The EQ-5D is an international, standardized, nondisease-specific (i.e., generic) instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their health state:
I am not anxious or depressed; I am moderately anxious or depressed; I am extremely anxious or depressed. In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of patients in that category.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score</title>
          <description>The EQ-5D is an international, standardized, nondisease-specific (i.e., generic) instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their health state:
I am not anxious or depressed; I am moderately anxious or depressed; I am extremely anxious or depressed. In the table below, each row title lists Baseline health status first followed by End of Treatment health status and reports the number of patients in that category.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No anxiety → No anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="76"/>
                    <measurement group_id="O6" value="36"/>
                    <measurement group_id="O7" value="81"/>
                    <measurement group_id="O8" value="78"/>
                    <measurement group_id="O9" value="76"/>
                    <measurement group_id="O10" value="80"/>
                    <measurement group_id="O11" value="44"/>
                    <measurement group_id="O12" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No anxiety → Moderate anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No anxiety → Extreme anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No anxiety → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate anxiety → No anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="35"/>
                    <measurement group_id="O9" value="28"/>
                    <measurement group_id="O10" value="33"/>
                    <measurement group_id="O11" value="15"/>
                    <measurement group_id="O12" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate anxiety → Moderate anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="22"/>
                    <measurement group_id="O9" value="19"/>
                    <measurement group_id="O10" value="26"/>
                    <measurement group_id="O11" value="8"/>
                    <measurement group_id="O12" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate anxiety → Extreme anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate anxiety → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme anxiety → No anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme anxiety → Moderate anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme anxiety → Extreme anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme anxiety → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → No anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Moderate anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Extreme anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data → Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Treatment in European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)</title>
        <description>The EQ-5D is an international, standardized, generic instrument for describing and evaluating health status. Health status is assessed by patients evaluating their health on a vertical, visual analog scale from 0 to 100 where the endpoints are labeled 'Worst imaginable health state' (=0) and 'Best imaginable health state' (=100). On the EQ-5D VAS, a positive change from baseline indicates improvement.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment in European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)</title>
          <description>The EQ-5D is an international, standardized, generic instrument for describing and evaluating health status. Health status is assessed by patients evaluating their health on a vertical, visual analog scale from 0 to 100 where the endpoints are labeled 'Worst imaginable health state' (=0) and 'Best imaginable health state' (=100). On the EQ-5D VAS, a positive change from baseline indicates improvement.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="75"/>
                <count group_id="O7" value="144"/>
                <count group_id="O8" value="145"/>
                <count group_id="O9" value="139"/>
                <count group_id="O10" value="146"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="21.11"/>
                    <measurement group_id="O2" value="5.8" spread="19.38"/>
                    <measurement group_id="O3" value="14.3" spread="22.38"/>
                    <measurement group_id="O4" value="11.1" spread="19.26"/>
                    <measurement group_id="O5" value="11.9" spread="21.33"/>
                    <measurement group_id="O6" value="13.3" spread="21.81"/>
                    <measurement group_id="O7" value="11.6" spread="21.94"/>
                    <measurement group_id="O8" value="12.5" spread="19.95"/>
                    <measurement group_id="O9" value="11.8" spread="18.91"/>
                    <measurement group_id="O10" value="15.9" spread="20.94"/>
                    <measurement group_id="O11" value="15.3" spread="24.17"/>
                    <measurement group_id="O12" value="11.1" spread="23.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Treatment in Work Productivity and Activity Impairment (WPAI)</title>
        <description>This 6-item assessment measures productivity losses during the past 7 days and includes measures on work time missed due to health, impairment while working due to health (the participant’s assessment of the degree to which health affected their productivity while working), overall work impairment due to health (takes into account both hours missed due to health and the participant’s assessment of the degree to which health affected their productivity while working) and activity impairment due to health (the degree in which health problems affected their ability to do regular daily activities). Scores for each measure are expressed from 0 to 100 with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment in Work Productivity and Activity Impairment (WPAI)</title>
          <description>This 6-item assessment measures productivity losses during the past 7 days and includes measures on work time missed due to health, impairment while working due to health (the participant’s assessment of the degree to which health affected their productivity while working), overall work impairment due to health (takes into account both hours missed due to health and the participant’s assessment of the degree to which health affected their productivity while working) and activity impairment due to health (the degree in which health problems affected their ability to do regular daily activities). Scores for each measure are expressed from 0 to 100 with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicates improvement.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="146"/>
                <count group_id="O8" value="147"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="78"/>
                <count group_id="O12" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent work time missed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.44" spread="10.580"/>
                    <measurement group_id="O2" value="0.53" spread="3.031"/>
                    <measurement group_id="O3" value="-0.24" spread="1.988"/>
                    <measurement group_id="O4" value="-2.85" spread="11.205"/>
                    <measurement group_id="O5" value="-1.29" spread="12.606"/>
                    <measurement group_id="O6" value="-0.28" spread="2.737"/>
                    <measurement group_id="O7" value="-0.55" spread="12.816"/>
                    <measurement group_id="O8" value="-0.83" spread="17.199"/>
                    <measurement group_id="O9" value="-0.84" spread="5.330"/>
                    <measurement group_id="O10" value="-1.65" spread="4.654"/>
                    <measurement group_id="O11" value="0.79" spread="6.757"/>
                    <measurement group_id="O12" value="-1.12" spread="11.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent impairment while working</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.50" spread="24.539"/>
                    <measurement group_id="O2" value="-16.13" spread="24.314"/>
                    <measurement group_id="O3" value="-10.00" spread="22.220"/>
                    <measurement group_id="O4" value="-16.67" spread="25.207"/>
                    <measurement group_id="O5" value="-17.33" spread="22.689"/>
                    <measurement group_id="O6" value="-10.00" spread="17.728"/>
                    <measurement group_id="O7" value="-8.43" spread="27.523"/>
                    <measurement group_id="O8" value="-17.72" spread="26.187"/>
                    <measurement group_id="O9" value="-13.85" spread="27.664"/>
                    <measurement group_id="O10" value="-13.39" spread="24.515"/>
                    <measurement group_id="O11" value="-18.00" spread="29.642"/>
                    <measurement group_id="O12" value="-9.29" spread="26.377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent overall work impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.50" spread="24.090"/>
                    <measurement group_id="O2" value="-16.32" spread="24.653"/>
                    <measurement group_id="O3" value="-9.91" spread="21.464"/>
                    <measurement group_id="O4" value="-17.88" spread="28.134"/>
                    <measurement group_id="O5" value="-17.26" spread="25.196"/>
                    <measurement group_id="O6" value="-9.95" spread="17.988"/>
                    <measurement group_id="O7" value="-8.59" spread="29.521"/>
                    <measurement group_id="O8" value="-17.16" spread="27.695"/>
                    <measurement group_id="O9" value="-14.00" spread="27.384"/>
                    <measurement group_id="O10" value="-14.18" spread="25.092"/>
                    <measurement group_id="O11" value="-17.69" spread="29.323"/>
                    <measurement group_id="O12" value="-10.32" spread="27.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent activity impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.62" spread="26.989"/>
                    <measurement group_id="O2" value="-14.52" spread="27.439"/>
                    <measurement group_id="O3" value="-13.95" spread="26.386"/>
                    <measurement group_id="O4" value="-13.73" spread="27.052"/>
                    <measurement group_id="O5" value="-14.38" spread="24.182"/>
                    <measurement group_id="O6" value="-17.12" spread="27.813"/>
                    <measurement group_id="O7" value="-14.11" spread="31.398"/>
                    <measurement group_id="O8" value="-25.31" spread="26.158"/>
                    <measurement group_id="O9" value="-17.43" spread="29.008"/>
                    <measurement group_id="O10" value="-20.42" spread="27.094"/>
                    <measurement group_id="O11" value="-19.34" spread="27.439"/>
                    <measurement group_id="O12" value="-19.74" spread="30.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Treatment in Treatment Satisfaction on Visual Analog Scale (TS-VAS)</title>
        <description>The TS-VAS is a visual analog scale (VAS) that asks patients to rate their satisfaction with treatment by placing a vertical mark on a 10 cm line where the endpoints are labeled 'No, not at all' on the left (=0) to 'Yes, completely satisfied' on the right (=10). A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 2.5 mg</title>
            <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg</title>
            <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 10 mg</title>
            <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Solifenacin 2.5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Solifenacin 2.5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Solifenacin 10 mg + Mirabegron 25 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Solifenacin 10 mg + Mirabegron 50 mg</title>
            <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment in Treatment Satisfaction on Visual Analog Scale (TS-VAS)</title>
          <description>The TS-VAS is a visual analog scale (VAS) that asks patients to rate their satisfaction with treatment by placing a vertical mark on a 10 cm line where the endpoints are labeled 'No, not at all' on the left (=0) to 'Yes, completely satisfied' on the right (=10). A positive change from Baseline indicates improvement.</description>
          <population>Full analysis set participants with available Baseline and post-baseline data; LOCF imputation was used</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="147"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="141"/>
                <count group_id="O8" value="143"/>
                <count group_id="O9" value="136"/>
                <count group_id="O10" value="144"/>
                <count group_id="O11" value="76"/>
                <count group_id="O12" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="0.298"/>
                    <measurement group_id="O2" value="2.61" spread="0.307"/>
                    <measurement group_id="O3" value="3.17" spread="0.301"/>
                    <measurement group_id="O4" value="3.10" spread="0.303"/>
                    <measurement group_id="O5" value="2.78" spread="0.217"/>
                    <measurement group_id="O6" value="2.96" spread="0.307"/>
                    <measurement group_id="O7" value="2.96" spread="0.221"/>
                    <measurement group_id="O8" value="3.24" spread="0.220"/>
                    <measurement group_id="O9" value="3.47" spread="0.225"/>
                    <measurement group_id="O10" value="3.24" spread="0.219"/>
                    <measurement group_id="O11" value="3.51" spread="0.301"/>
                    <measurement group_id="O12" value="3.72" spread="0.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Statistical comparisons were made using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.
The ANCOVA model for all pairwise comparisons includes the 2 main factors mirabegron dose and solifenacin succinate dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.
LS Mean Differences were calculated by subtracting Solifenacin 5 mg/Placebo from the comparison treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.376</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.310</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.308</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.313</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.308</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.371</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.368</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.428</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.423</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.425</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.369</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.428</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.371</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.371</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.373</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.369</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.423</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>1.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.421</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events summarized for the Safety Analysis Set (SAF) were reported after the first dose of double-blind study drug and no more than 30 days after the last dose of double-blind study drug.</time_frame>
      <desc>The SAF included all patients randomized to a double-blind treatment who took at least 1 dose of study drug.One participant randomized to the Mirabegron 25 mg arm received treatment with Solifenacin 5 mg + Mirabegron 50 mg in error and is counted in that arm for safety analysis set analyses.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received matching placebo tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Mirabegron 25 mg</title>
          <description>Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Mirabegron 50 mg</title>
          <description>Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Solifenacin 2.5 mg</title>
          <description>Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Solifenacin 5 mg</title>
          <description>Participants received solifenacin 5 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Solifenacin 10 mg</title>
          <description>Participants received solifenacin 10 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Solifenacin 2.5 mg and Mirabegron 25 mg</title>
          <description>Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Solifenacin 2.5 mg and Mirabegron 50 mg</title>
          <description>Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="E9">
          <title>Solifenacin 5 mg and Mirabegron 25 mg</title>
          <description>Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="E10">
          <title>Solifenacin 5 mg and Mirabegron 50 mg</title>
          <description>Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="E11">
          <title>Solifenacin 10 mg and Mirabegron 25 mg</title>
          <description>Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks.</description>
        </group>
        <group group_id="E12">
          <title>Solifenacin 10 mg and Mirabegron 50 mg</title>
          <description>Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Trigeminal nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="33" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="36" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="34" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="40" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="39" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="30" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="35" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="21" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="20" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="16" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="14" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="156"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="149"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site’s manuscript at least 90 days prior to publication for review and comment.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Astellas Pharma Europe, B.V.</organization>
      <email>Astellas.resultsdisclosure@astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

